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1 Introduction 
1.1 The NADPH oxidases (NOX) 
The NADPH Oxidase (NOX) enzymes are transmembrane electron transporters. They 
transport electrons from the cytoplasmic electron donor NADPH to molecular oxygen 
and, which is reduced to superoxide anion radicals [1, 2]. The function of each NADPH 
oxidase requires the interaction of at least two cytosolic proteins, including GTPases, 
phox proteins, and proteins of the cytoskeleton. In mammalian cells seven NOX 
proteins have been identified, namely NOX1, NOX2, NOX3, NOX4, NOX5 and DUOX1 
and DUOX2. All of these proteins differ in their mode of activation, expression, and 
interaction with other proteins and possibly in the type of ROS formed [3].   
1.2 NOX1 
Superoxide generation by NOX1 depends on subunits, such as small membrane bound 
protein p22phox, cytosolic subunits NOXO1 (NOX organizer 1= p47phox homolog) and 
NOXA1 (NOX activator 1 = p67phox homolog) and small GTPase binding protein Rac 
(see Figure 1) [2, 4]. NOX1 is highly expressed in colon but also found in intermediate-
to- low amounts in smooth muscle, endothelium, fibroblasts, prostate and uterus [1, 5, 
6]. The Best known function of NOX1 is in the vascular system, where it plays a 
prohypertensive role, particularly after angiotensin II stimulation [7]. 
1.3 NOX2 
NOX2 is the prototype NOX, also known as gp91phox. Activation of NOX2 requires 
membrane bound p22phox, cytosolic proteins p47phox, p67phox and p40phox. 
p22phox helps to stabilize the NOX proteins. The organizer protein p47phox is 
phosphorylated upon cell activation and translocated to the membrane p22phox along 
with activator p67phox, the GTP binding protein Rac and modulator protein p40phox. 
After translocation of p67phox to the membrane, it directly interacts with NOX2 and 
activates the enzyme [1, 2]. NOX2 is most abundant in phagocytes [1, 2, 6, 8] and lower 
but quantitatively significant amounts are found in kidney [9], smooth muscle cells, and 
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fibroblast [8]. The well known function of NOX2 is microbial killing [8]. In addition NOX2 
might be involved in ageing, particularly through an inflammatory process [10].     
 
 
Figure 1: Schematic diagram of NOX1 and NOX2 and activation by their cytosolic subunits 
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Figure 2: Schematic diagram of NOX4 and activation by its cytosolic subunits.  
1.4 NOX3 
NOX3 activation needs the stabilizer protein p22phox, but it is not clear whether 
cytosolic proteins are involved. NOX3 probably exhibits the most specific and restricted 
tissue expression. It is essentially found in the inner ear, both the vestibular and the 
auditive part [11, 12]. 
1.5 NOX4 
NOX4 shares only about 39% identity with NOX2. NOX4 activation requires p22phox 
but most likely no cytosolic proteins such as p47phox, p67phox and p40phox. This 
enzyme is highly expressed in the kidney and endothelial cells [2] and also present in 
embryonic stem cells, fibroblasts, osteoclasts and neurons [1]. NOX3, NOX5, DUOX1 
and DUOX2 are calcium dependent and produce hydrogen peroxide.  
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1.6 The organizer protein p47phox 
p47phox [13, 14] is a cytosolic organizer protein for NOX2 [2] and it shares about 25% 
sequence identity to its homolog NOXO1 (organizer for NOX1). Both organizer subunits 
play a similar function for their target enzymes. However, p47phox has an autoinhibitory 
region, which inhibits the translocation to the plasma membrane, which is absent in 
NOXO1. Phosphorylation of the autoinhibitory domain in p47phox allows association 
with p22phox [2]. p47phox is highly expressed in myeloid cells [14], and also in 
glomerular mesangial cells [15], endothelial cells [16], vascular smooth muscle cells, 
testis, inner ear, neurons, hepatocytes and lung [2].     
1.7 DNA as the oxidation target  
When there is imbalance between ROS and endogenous antioxidants the oxidative 
stress is increased (Figure 3).  The free radical theory of ageing was first proposed by 
Denham Harman [17]. There is an emerging consensus that oxidative damage is of 
central importance. Lipid, protein and DNA are the key targets for oxidation. Although 
oxidation of lipids and proteins accumulates with age, only DNA oxidation leads to 
altered genomic information [18].  
 
Many types of base and sugar damage occur in DNA after an attack by ROS. Some of 
these result in disruptions of the phosphodiester backbone, which give rise to single 
stranded (ss) DNA nicks of various configurations [19].  Among the chemical events that 
can affect DNA is an oxidation of guanine to 7,8-dihydro-8-oxo-2-deoxyguanosine (8-
oxodG) [10]. Similar to the other types of damage, this lesion is efficiently repaired by at 
least two pathways of base excision repair. The steady-state level of 8-oxodG events is 
100 – 1,000 per cell in mice, but the number of these events that fail to be repaired and 
become point mutations is less clear. Some studies report that there is no detectable 
increase in the steady-state level of nuclear 8-oxodG with age [10, 20], although others 
have reported an increase [21, 22]; detailed information can be found in a recent review 
[23]. Another report indicates that there is an accumulation of failed repair sites for 8-
oxodG in aged mice [24]. 
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Figure 3: Oxidative stress by an imbalance between ROS and endogenous antioxidants.  
 
1.8 Formation of 8-oxodG 
Superoxide, the primary product of NOX, is produced physiologically via a one-electron 
reduction of molecular oxygen. Superoxide is highly reactive and short lived and can 
dismutate to a second oxidant intermediate, H2O2, spontaneously or enzymatically via 
superoxide dismutase (SOD). Hydrogen peroxide is more stable than superoxide and is 
also capable of crossing biological membranes [25]. Reduction of hydrogen peroxide to 
water is accomplished by catalase and glutathione peroxidase. However, in the 
presence of transition metals such as iron or copper, hydrogen peroxide is reduced to 
hydroxyl radicals(•OH) which is the most deleterious ROS [26, 27]. Kasai and Nishimura 
(1986) were the first to report that the reaction of •OH with nucleobases of the DNA 
strand, such as guanine, leads to the formation of 8-oxo-7,8-dihydro-2‟-
deoxyguanosine. Initially, the reaction of the •OH addition leads to the generation of 
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radical adducts, then by one electron abstraction, 8-hydroxy-2‟-deoxyguanosine (8-
OHdG) is formed (Figure 4). 8-OHdG undergoes keto-enol tautomerism,  and turns into 
the oxidized product 8-oxodG (Figure 4 and 5) [28]. The mechanistic models of one-
electron oxidation reactions of the guanine base in isolated DNA and chemical reactions 
in the context of •OH radical, singlet oxygen, and two-quantum photoionization 
processes were reviewed recently [29-31]. The formation of 8-oxodG can lead to 
chromosomal aberrations and the induction of mutations, which mainly involve GC to 
TA transversions [32, 33]. 
 
HN
N
N
H
N
H2N
O
O
OH
CH2HO
HN
N
N
N
H2N
OH
O
OH
CH2HO
HN
N
N
N
H2N
O
OH
CH2HO
.
OH
2'-deoxyguanosine 8-hydroxy-2'-deoxyguanosine 8-oxo-7,8-dihydro-2'-deoxyguanosine
 
Figure 4: The oxidation of deoxyguanine by hydroxyl radicals leads to the generation of 8-
hydroxy-2‟-deoxyguanosine (8-OHdG) which undergoes keto-enol tautomerism, and turns into 
the oxidized product 8-oxo-7,8-dihydro-2‟-deoxyguanosine (8-oxodG). 
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Figure 5: Possible adducts formed by different radicals with guanine; the hydroxyl radical at the 
8th position is most favorable and it is an important pro-mutagenic biomarker. (The modified 
figure was adopted from Singh et al [34] with permission from Oxford University Press, 2006).  
 
1.9 Cellular 8-oxodG 
Cellular 8-oxodG is a direct biomarker for oxidative DNA damage and has been 
extensively analyzed in humans (leukocytes), rats (liver, lung, kidney, brain, heart, colon 
and testis), mice (liver, lung, kidney, brain, heart, aorta, mammary gland, uterus and 
small intestine) and cultured cells. 8-oxodG is quantified using high performance liquid 
chromatography coupled to an electrochemical detector (HPLC-ECD), mass 
spectrometry (HPLC-MS), or tandem mass detection (HPLC-MS/MS), immunoassays, 
32P-postlabeling and a modified single-cell gel electrophoresis (comet) assay. In the 
1990‟s HPLC and gas chromatography coupled with mass spectrometer (GC-MS) were 
commonly used for the analysis of 8-oxodG. The reported values for normal human 
cellular 8-oxodG varied up to 1000 fold depending on the method of analysis. The 
question of artifact formation of 8-oxodG during the analytical procedure was raised 
[35]. To resolve the possible methodological problems for cellular 8-oxodG analysis, the 
European Standard Committee on Oxidative DNA Damage (ESCODD) was set up in 
1997. 
  Introduction 
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1.10  Artifact formation during 8-oxodG analysis 
In the ESCODD validation trial, a variety of methods (HPLC, HPLC-ECD, HPLC-
MS/MS, GC-MS and enzymatic assays) were used to minimize the artifactual formation 
of 8-oxodG. As a result of the trial, it became acknowledged that artifact formation 
occurs during DNA isolation and sample preparation [36]. In 2002, Ravanat et. al. 
reported that the use of desferrioxamine (a transition metal chelator), in the extraction 
buffers and of sodium iodide (a chaotropic agent which helps in DNA precipitation), 
could minimize the artifact formation [37]. Other ESCODD trials found that the HPLC-
ECD method is an accurate method for analyzing 8-oxodG, but that the background 
levels vary considerably. This was recognized to be due to uncontrolled sample 
preparation (DNA hydrolysis) [38]. Singh et al., [39] introduced the immunoaffinity 
column combined with tandem mass spectrometry, as well as the use of the stable 
isotope 15N5-8-oxodG as an internal standard. The advantage of this method is that it is 
more specific because of the affinity of the antibody to 8-oxodG. Furthermore, the 
addition of the internal standard 15N5-8-oxodG can account for loss during the sample 
preparation. After a lot of inter-laboratory trials, ESCODD concluded with some difficulty 
that the background 8-oxodG level in human lymphocytes is between 0.3 and 4.2/106dG 
[40].  
 
Concerning HPLC-MS/MS based methods, the online sample extraction using a 
column-switching device has proven to be an extremely useful technique for sample 
preparation from biological matrices [41]. Its advantages include automatic sample 
preparation and less ion suppression as well as higher sensitivity, plus selectivity due to 
a direct measurement of DNA adducts in crude hydrolysates [42]. In the case of 8-
oxodG analysis, the artifactual oxidation of dG occurs especially during DNA 
preparation, which by use of online extraction could be minimized. Chao et al attempted 
to minimize the artifactual production of 8-oxodG during DNA preparation and the 
electrospray ionization process, using an isotope-dilution LC–MS/MS method coupled 
with an online solid-phase extraction (SPE) system for the direct and simultaneous 
analysis of 8-oxodG and dG in crude DNA hydrolysates [43]. The method proposed by 
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Chao et al gave a low level of 8-oxodG/106 dG [44], We found 2.0 8-oxodG/106 dG in  
rat liver DNA, 1.1 in human leukaemia HL-60 cells, and 2.6 in neuronal PC-12 cells 
(Figure 6). The relative standard deviation of replicates was 20%. Positive controls (HL-
60 cells incubated for 10 min with 10 µg/mL methylene blue in the presence of a 60 W 
lamp at 10 cm distance) showed 32 8-oxodG/106 dG (Figure 6). The values of 8-oxodG 
analyzed by this method were within the limit of ESCODD-suggested levels between 0.5 
and 5 lesions per 106 dG bases [45]. 
 
Figure 6: The histogram displays the background level of 8-oxodG in rat, and different cell line 
and lymphocyte DNA. HL= Human promyelocytic leukemia cells; LLC-PK1= pig kidney proximal 
tubule cells; MDCK= Madin-Darby canine kidney cell line; PC-12= pheochromocytoma of 
the rat adrenal medulla. 
1.11  Urinary 8-oxodG 
Urine is the most frequently examined matrix for 8-oxodG, because of the non-invasive 
nature, easy sampling and storage (stable for more than 10 years) and the possibility to 
conduct large studies. However, there is a considerable debate about the possible 
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sources of extracellular oxidatively modified DNA lesions. DNA repair, diet, cell death or 
cell turnover, mitochondrial turnover, cellular uptake and re-utilisation of damage 
products are possible contributions to urinary 8-oxodG (see recent reviews) [46, 47].  
1.12  Reduced and oxidized glutathione  
Glutathione (GSH γ-L-glutamyl-L-cysteinylglycine), and its oxidized form disulfide 
glutathione (GSSG) (Figure 7) comprise the most abundant cellular redox system, 
playing a fundamental role in cell homeostasis. It is also involved in signaling processes 
associated with programmed cell death. Alteration of the redox balance causes 
oxidative damage [48]. The biologically active site of GSH is represented by the thiol 
group on the cystine residue (Figure 8). The de novo biosynthesis of GSH requires two 
ATP-dependent enzymes. Glutamic acid and cystein get converts into γ-glutamyl-
cysteine in the presence of γ-glutamyl-cysteine synthetase. This step can be blocked by 
dl-Buthionine-sulfoximine (BSO). The γ-glutamyl-cysteine is converted into GSH by 
glutathione synthase [49]. Both, direct and glutathione peroxidase-mediated enzymatic 
oxidation of GSH lead to the formation of GSSG. Reduction of GSSG leads to GSH 
formation in the presence of glutathione reductase (GR) as NADPH dependent reaction 
(Figure 9) [50, 51]. The activity of GR and availability of NADPH are sufficient to 
maintain the molar ratio of GSSG: GSH about 1:100. However, if the level of stress is 
increased or the GR activity is limited, then there is accumulation of GSSG and the 
molar ratio of the GSSG/GSH increases [48, 52]. 
              
 
 
 
 
 
 
Figure 7: Structure of oxidized glutathione (GSSG)  
HO
O O
H
N
N
H
O
O
H
O
H
H
S
S
N
H
H
H
N
HO
O
H
O
H2N
O
H
O O
H2N
  Introduction 
 
11 
 
 
 
 
 
 
 
Figure 8: Structure of reduced glutathione (GSH) 
 
 
 
Figure 9: Biosynthetic pathway for reduced (GHS) and oxidized glutathione (GSSG). GCS= 
gltamylcysteine synthetase;  GSS= glutathione synthetase; GR= glutathione reductase; GPX= 
glutathione peroxydase; GCS= gltamylcysteine synthetase; BSO= dl-Buthionine-sulfoximine   
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1.13  8-isoprostaglandin F2α (8-isoPGF2α) 
8-isoPGF2α (Figure 10) is a specific and stable lipid peroxidation product. 8-isoPGF2α 
has received more attention than all other 64 isomers. Because it has been shown to 
act as a potent renal and pulmonary vasoconstrictor, platelet aggregation modulator, 
inflammatory mediator [53-55]. National Institute of Health (NIH) organized Biomarkers 
of Oxidative Stress Study (BOSS) concluded 8-isoPGF2α is a most accurate biomarker 
of oxidative stress [56].  
 
 
Figure 10: Structure of 8-isoprostaglandin (8-isoPGF2α)  
1.14  8-Nitroguanine (8-nitroG) 
8-Nitroguanine (8-nitroG) is known to be a mutagenic product from the guanine base of 
DNA that induces GC to AT transversion mutation. Nitric oxide (NO) reacts with 
superoxide to form highly reactive peroxynitrite (ONOO−), which causes the nitrative 
DNA lesion 8-nitroguanine (Figure 11) [57, 58]. 
 
 
 
 
Figure 11: Structure of 8-nitroguanine (8-nitroG)  
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1.15  Creatinine 
Creatinine (Figure 12) is a cyclic derivative of creatine. Creatinine clearance determines 
the quantitative kidney damage. Creatinine clearance can be measured by calculating 
the amount of serum creatinine filtered by the glomerulus at a unit of time [59]. 
Creatinine is a breakdown product of creatinine phosphate, and the amount depends on 
the muscle tissue in the body and the renal function. The creatinine rate of excretion is 
relatively constant over time. Therefore, most of the urinary markers are commonly 
normalized to creatinine [60].  
 
 
Figure 12: Chemical structure of creatinine  
 
1.16  NOX activation by Ang II 
Ang II (Figure 13) activates NOX in cardiovascular, kidney and central nervous systems. 
In general, Ang II binds to its receptor AT1R, activates NOX (Figure 14) and produces 
ROS. However, the complete mechanisms of NOX activation by Ang II are complex and 
still incompletely understood [61]. 
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Figure 13: Chemical structure of Ang II  
 
 
Figure 14: Nox activation by Ang II via AT1 receptor and production of superoxide anion 
radicals 
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1.17  Aldosterone  
Aldosterone (Figure 15) is synthesized from cholesterol in the zona glomerulosa (ZG) of 
the adrenal cortex. A number of factors have been shown to stimulate or inhibit 
aldosterone production. However, the major regulator of aldosterone synthesis and 
secretion is Ang II [62]. Aldosterone causes oxidative stress via upregulation of the 
expression of the NOX subunits [63]. It induces a genotoxic effect in LLC-PK1 cells via 
production of superoxide anion and hydrogen peroxide [64, 65].    
 
 
 
 
 
 
 
Figure 15: Chemical structure of aldosterone  
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1.18  Rosuvastatin  
The structural formula of rosuvastatin shown in Figure 16. 
 
Figure 16: Chemical structure of rosuvastatin calcium salt  
 
Statins are lipid lowering drugs. They inhibit 3-hydroxy-3methylglutaryl-coenzyme A 
(HMG-CoA) reductase which catalyses the rate limiting step for cholesterol biosynthesis 
[66]. In addition to the lipid lowering effect, statins shows pleiotropic actions including 
anti-inflammatory, anti-thrombotic and antioxidant effects. Recently we have shown that 
rosuvastatin exerts antioxidative effects, and it prevents from oxidative stress induced 
DNA damage. This anti-oxidant effect is, probably mediated via up-regulation of 
glutathione synthesis [67]. Moreover, rosuvastatin reduces an elevated level of 
angiotensin II type 1 receptor (AT1R) and protects the vascular system [68].  
1.19  Parkinson’s Disease and oxidative DNA damage 
Parkinson‟s disease (PD) is the most common neurodegenerative movement disorder 
affecting approximately 2% of the human population aged 65 and above [69]. While the 
full clinical syndrome of PD is a complex disorder, the characteristic motor symptoms 
associated with the sporadic and all genetic forms of this disorder result from the 
degeneration of the dopamine-producing neurons of the substantia nigra (SN). This is 
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the rationale for the dopamine-substitution therapies, including treatment with L-3,4-
dihydroxyphenylalanine, levodopa (L-DOPA) and peripheral aromatic amino acid 
decarboxylase- and catecholamine-O-methyltransferase inhibitors, selective 
monoamine oxidase type B inhibitors, dopamine receptor agonists and drugs which 
indirectly improve dopaminergic functions (for example, glutamate antagonists). While 
the trigger for this relatively selective neuronal vulnerability remains unknown. The 
cascade of degenerative events leading to cell death is beginning to be understood. The 
major hypotheses believed to contribute to the eventual demise of dopamine producing 
cells in the SN include protein aggregation, oxidative stress, disturbed iron metabolism, 
mitochondrial dysfunction and dysfunction of proteasomal pathways [70-74]. 
L-DOPA has been the most frequently prescribed drug for alleviating symptoms of PD in 
the last three decades. However, the contribution of L-DOPA therapy to oxidative 
damage is still debated. There is evidence for the toxic properties of L-DOPA to 
neuronal cells in vitro [75, 76], however this toxicity has not been confirmed in healthy 
rodents [77], nonhuman primates [78] or humans [79]. Moreover, the recent clinical 
trials did not supply proof for toxic effects of L-DOPA which would contribute to PD 
progression [80]. 
In the postmortem SN of PD patients concentrations of the oxidized DNA-base 8-oxodG 
are markedly increased compared to controls [81, 82]. Migliore, et al. reported an 
increased frequency of micronuclei, a subset of chromosomal aberrations, and of single 
strand breaks and oxidized purine bases in the peripheral blood leukocytes of patients 
with untreated PD [83]. Recently, large cohort studies revealed a correlation between 
frequencies of chromosomal aberrations or micronuclei in peripheral lymphocytes and 
cancer risk [84, 85]. In addition, even sublethal damage of cellular nucleic acids or 
genomic damage may contribute to the further degeneration of neuronal cells, thus 
enhancing the progression of the disease [86-88]. 
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1.20  Electro Spray Ionisation (ESI) and Multiple Reaction Monitoring 
(MRM) in Liquid Chromatography-Tandem Mass Spectrometry 
(LC-MS/MS)  
1.20.1 Electro Spray Ionisation (ESI) 
Electrospray ionization (ESI) is a popular technique in mass spectroscopy for ionizing 
biological or chemical molecules. ESI works well with many different types of 
compounds. This technique works well with larger and small molecules; therefore, it is 
used in proteomics (analysis of proteins), lipidomic (analysis of lipids) and metabolomics 
(analysis of metabolites). The working process of ESI consists of two stages (Figure 17) 
[89]. 
 
First, the sample or analytes are dissolved in a mobile phase which consists of organic 
solvents and acidified water or buffer.   This analytes are separated in a HPLC and 
introduced into a vessel, called a capillary, that ends in a very fine tip. A very high 
voltage is applied to this tip, which charges the analytes molecule in the solvent. The 
charged analytes are entered into the evaporation chamber. Then the molecules repel 
one another almost violently. When the charged liquid first exits the tip, it briefly forms a 
cone shape known as a Taylor cone.  The charged cone shape liquid droplets burst 
away from each other into a fine spray [89, 90]. 
 
Second, the charged droplets in the spray go through a series of divisions. This occurs 
because the solvent within these droplets gradually evaporates with the assistance 
of nitrogen gas pumped into the chamber and forms smaller droplet ions. When these 
ions are pushed close enough together, they will repel each other this behavior is 
known as the Coulomb force and causing the droplets to divide into two smaller 
droplets. This process repeats itself until the solvent is completely evaporated and the 
droplets have split up to the point that each is a single, charged molecule. The single 
charged molecules enter into the mass detector. One of the advantages of this 
ionization method is that the molecules remain intact and will not be broken apart, that 
is why this ionization is called soft ionization technique [89, 90]. 
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Figure 17: Electro spray ionization process in LC-MS/MS. The schematic diagram with the 
permission of Cech and Enke [89] (copy right permission from John Wiley and Sons, 2001). 
1.20.2 Multiple reaction monitoring (MRM) 
Multiple reaction monitoring (MRM) coupled with stable isotope dilution mass 
spectrometry using a triple quadrupole mass spectrometer is a powerful tool for 
quantitative measurement of target molecule in metabolomics, proteomics [91], 
lipidomics etc. [34, 92-94].   
In MRM mode, two stages (Figure 18) of mass filtering are employed on a triple 
quadrupole mass spectrometer [94]. In the first stage, the ionized m/z of a precursor ion 
is filtered in the first quadrupole (Q1). The selected precursor ion is dispersed into 
several fragment ions in the second quadrupole (Q2) by collision excitation with a 
neutral gas in a pressurized collision cell. In the second stage, only the interesting m/z 
mass of the fragment ions can pass into the third quadrupole (Q3) [92]. Therefore the 
intensities of these ions are measured and converted to concentrations. The MRM triple 
quadrupole LC-MS/MS measures up to 2500 transitions in a single assay [92, 93]. 
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Figure 18: Multiple reaction monitoring process in triple quadrupole mass analysis. The 
precursor ions from the ion source are pushed into first (Q1) quadrupole (MS1 level) and  
selectively allows only the targeted parent ions to pass into second (Q2) quadrupole for 
collision-induced dissociation (CID) fragmentation. The third (Q3) quadrupole (MS2 level) 
selectively allows only a specific pre-identified fragment ion to pass to detector [94]. 
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2 Objectives 
NADPH oxidase (NOX) produces reactive oxygen species (ROS). The imbalance 
between ROS and endogenous antioxidants leads to oxidative stress. Since Harman 
proposed the "free-radical theory of aging", more than 50 years ago oxidative stress has 
been postulated to be a major fundamental factor for ageing and age related diseases. 
There is an emerging consensus that oxidative damage is of central importance. Lipid, 
protein and DNA are the key targets for oxidation. Although oxidation of lipids and 
proteins accumulates with age, only DNA oxidation leads to altered genomic 
information. 
I). Nowadays there are a lot of reports suggesting that oxidative stress-induced 
oxidative DNA damage is accumulated in animal organs during the ageing process 
[23].  
 We wanted to study the influence of NADPH oxidase (NOX) derived 
reactive oxygen species (ROS) induced oxidative DNA damage. Therefore 
we compared WT mice (C57BL/6J) with p47phox-/- (deletion of NOX 
organizer subunit p47phox) mice.  
 To study the role of NOX derived ROS in ageing, we compared young and 
older WT mice (C57BL/6J) with p47phox-/- mice in the context of oxidative 
stress and oxidative DNA damage. 
To analyze oxidative stress and oxidative DNA damage markers, we developed a 
new isotope- diluted-LC-ESI-MS/MS method and validated it to analyze 8-oxodG, 8-
isoPGF2α, GSH, GSSG, Ang II, Aldosterone and creatinine in a single sample 
preparation. 
Using this method, we analyzed the oxidative DNA damage marker 8-oxodG in 
urine and kidney. The oxidative stress markers, urinary and plasma 8-isoPGF2α 
and the oxidized, reduced glutathione (GSSG/GSH ratio) from plasma were also 
analyzed by LC-ESI-MS/MS. The DNA strand breaks were analyzed in cells from 
liver, kidney, using the comet assay.  
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II). Statins are lipid lowering drugs. They inhibit 3-hydroxy-3methylglutaryl-coenzyme A 
(HMG-CoA) reductase which catalysis the rate limiting step for cholesterol 
biosynthesis [66]. In addition to the lipid lowering effect, statins shows pleiotropic 
actions including anti-inflammatory, anti-thrombotic and antioxidant effects. 
Recently we have shown that rosuvastatin exerts antioxidative effects, and it 
prevents DNA damage from oxidative stress. The antioxidant effect of rosuvastatin 
acts via up-regulation of glutathione synthesis [67]. Moreover, rosuvastatin reduces 
elevated levels of angiotensin II type 1 receptor (AT1R) and protects the vascular 
system [68].   
 Therefore we wanted to study the protective effect of rosuvastatin on Ang II 
induced oxidative stress and genomic damage in the pig kidney cell line LLC-
PK1.  
We analyzed genomic damage in the comet assay, 8-oxodG, micronuclei frequency, 
and endogenous antioxidant enzyme expressions such as glutathione synthetase, 
glutathione reductase and glutathioneperoxidase. 
 
 III). Parkinson's disease (PD) is a neurodegenerative movement disorder affecting about 
2% of the human population at old age. L-3,4-Dihydroxyphenylalanine (L-DOPA) in 
combination with a peripheral aromatic amino acid decarboxylase inhibitor is the most 
frequently prescribed drug for alleviating symptoms of PD, but a potential contribution 
of L-DOPA therapy to further neurodegeneration via oxidative stress is still debated.   
 We intended to elucidate, whether oxidative stress is elevated in chronically L-
DOPA-treated PD patients, and whether this leads to elevated genomic damage.  
Therefore we analyzed 8-oxodG in lymphocyte DNA of PD patients and matched 
controls. In addition, we assessed the antioxidant capacity of plasma, and the 
micronucleus frequency in peripheral lymphocytes.  
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Overall to analyze oxidative DNA damage and oxidative stress markers, we applied 
both new and European Standards Committee on Oxidative DNA damage (ESCODD) 
approved isotope-diluted-LC-ESI-MS/MS methods. Further we used comet assay, 
micronuclei frequency test for genomic damage assessment.  
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3 Materials and methods 
3.1 Materials   
3.1.1 Chemicals  
If not mentioned otherwise all chemicals were purchased from sigma-Aldrich.  N-methyl-
D3-creatinine, 98% from Cambridge Isotope Laboratory, Inc. MA, USA; 15N-dG, 98% 
from Silantes, Germany; Glycine-13C2,
15N-glutathione, >90%, from Cambridge isotope 
Laboratories, MA, USA;8-Nitroguanine from Santa cruz, CA, USA; 13C-15N labeled Ang 
II, >98%  from Eurisotop, Germany;  aldosterone-d7, >98, Isosciences, PA, USA;  8-
isoPGF2α  and 8-isoPGF 2α-d4, 99% from Cayman chemicals, MI, USA. HPLC-grade 
methanol and water for liquid chromatography were purchased from Roth, Karlsruhe, 
Germany; 
 
3.1.2 Animals  
p47phox knockout (p47phox-/-) and C57BL/6  wild type (WT) mice were kindly provided 
by Prof. Dr.  Rolf Schulte-Hermann (Institute for Cancer research, University of Vienna, 
Borschkegasse 8a, A-1090, Vienna, Austria).  p47phox-/-  mice were originally produced 
from embryonic stem cell 129/Sv-derived sperm and C57BL/6-derived eggs. All mice 
were bred in the breeding facilities of the Institute of Pharmacology and Toxicology, 
University of Wuerzburg, Germany. The animals were confirmed from ear DNA 
sequenced by PCR (Phire Animal Tissue Direct PCR kit; experiment was done by 
Simone Weissenberger, Department of Toxicolog, University of Wuerzburg, Germany).  
Additionally C57BL/6 wild type mice were purchased from Fa. Janvier, France. The 
mice were housed in Scantainers and care was provided according to the institutional 
animal care. In aging p47phox-/- mice granular structures (chronic granulomatous 
disease) are deposited in the lungs. However, even without antibiotics survival is 
possible for more than 14 months [95]. In our case the percent of animals which died 
spontaneously at our animal facility was 15.62%. 
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Urine was collected at the age of 12-13 weeks (13 weeks 5 days for WT; 12 weeks for 
p47phox-/- mice) and the plasma and tissue were collected at the age of 21-23 weeks 
(23 weeks 4 days for WT; 21 weeks 2 days for p47phox-/- mice). This was considered 
as young group. Urine, plasma and tissue from old WT mice were collected at the age 
of 52- 53 weeks (considered as old group) and the results were compared with relatively 
old phox-/- mice at the age of 30-32 weeks. For urine collection two animals were 
placed in a metabolic cage overnight, adequate food and water was supplied and the 
urine was collected and stored at -20°C. LLC-PK1 cells were cultured at 37°C, 5% (v/v) 
CO2 in Dulbecco‟s Modified Eagle Medium (DMEM) low glucose (1g/l) supplemented 
with 10 % (v/v) fetal bovine serum (FBS), 1% (w/v) L-glutamine, 2.5% (w/v) HEPES and 
antibiotics (50 U/ml penicillin, 50 μg/ml streptomycin). 
 
3.1.3 Extraction of primary kidney cells 
Freshly obtained mouse kidneys were minced on ice to small pieces, which were 
suspended in 3 ml buffer consisting of RPMI 1640, 15 % DMSO, 1.8 % (w/v) NaCl. The 
extracted primary rat kidney cells were sifted through a cell strainer with a mesh pore 
size of 100 µm (BD, Heidelberg, Germany), centrifuged for 5 minutes at 1000 rpm and 
at 4 °C and were finally resuspended in 1 ml Dulbecco‟s Modified Eagle Medium 
(DMEM) low glucose (1g/l) supplemented with 10 % (v/v) fetal bovine serum (FBS), 1% 
(w/v) L-glutamine, 2.5% (w/v) HEPES and antibiotics (50 U/ml penicillin, 50 μg/ml 
streptomycin) [96]. 
 
3.1.4 Cell line    
LLC-PK1 cells from pig kidney, which resemble proximal tubule cells, were obtained 
from the American Type Culture Collection (Manassas, VA, USA). Cell culture media 
and reagents were obtained from PAA Laboratories GmbH (Pasching, Austria). LLC-
PK1 cells were grown at 37°C in a humidified atmosphere of 5% CO2 in Dulbecco‟s 
modified Eagle‟s medium (DMEM) with 1000 mg/L glucose supplemented with 10% 
fetal calf serum (FCS; Gibco-BRL), 25 mM HEPES, 1% L-glutamine and 0.2% 
antibiotics (50U/mL penicillin, 50μg/mL streptomycin). Cells were routinely split twice a 
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week to keep the under-exponential-growth conditions. They were cultured for no more 
than 10 passages after thawing them from stock [97]. 
   
3.1.5 Subjects 
18 PD patients were enrolled in this study. Patient characteristics are summarized in 
table 7. Patients were treated with L-DOPA in a dose range of 188 to 1850 mg/day and 
dopa decarboxylase inhibitor, either carbidopa (25 to 425 mg/day) or benserazide (47 to 
187 mg/day) or both. Further medications included catechol-O-methyl transferase 
(COMT) inhibitors, dopamine agonists, antipsychotic drugs, and MAO inhibitors (Table 
8). Life-partners of PD patients were also enrolled in this study, yielding a matched 
control group. The study was approved by the University of Wuerzburg ethics 
committee and was carried out according to the declaration of Helsinki. A written 
consent was obtained from all patients prior to participation in the study. 
3.1.6 Collection of blood samples 
Blood samples were collected from patients and healthy controls for 8-oxodG and FRAP 
assay (1x7.5 ml), micronucleus analysis and L-DOPA quantification (1x7.5 ml). Blood 
samples were taken via an indwelling cannula and collected in coded tubes containing 
heparin. Samples were transported from the Leopoldina Hospital, Schweinfurt 
(Germany) to the Department of Toxicology at the University of Wuerzburg (Germany) 
at room temperature within 2-3 h and processed immediately.  
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3.2 Analytical methods 
3.2.1 A new LC-ESI-MS/MS method development and validation for 
analysis of 8-oxodG, 8-isoPGF2α, 8-nitroG, GSH, GSSG, dG, 
angiotensin II, aldosterone, and creatinine (analytes or markers)  
3.2.1.1 Synthesis of stable isotope labeled internal standards 
3.2.1.1.1 Synthesis of 15N-13C-GSSG 
Isotopically labeled GSSG was prepared using commercially available glycine-labeled 
GSH ([glycine 1,2-13C2,
15N]-GSH). For this, a solution of 2mM labeled GSH was treated 
with an equal volume of 16mM H2O2. The oxidant was gradually added to the reactant 
while the solution was stirred. The reaction was carried out at 25°C for 6h. 13C-15N-
GSSG was isolated using HPLC-UV with a Reprosil pur (150x4.6 mm; 5μm), column 
with a mobile phase of 10% MeOH in 0.1% TFA. The isocratic run time was 15 min and 
the flow rate 400μL/min, the analytes were detected at 210nm. The nature of the 
purified glycine-labeled GSSG was confirmed by mass spectrometry and quantified in 
the above mentioned HPLC-UV method using unlabeled GSSG standard [98, 99]. 
 
3.2.1.1.2 Synthesis of 15N-13C-GSH-NEM 
GSH was detected and quantified as GSH-NEM alkylated adduct. To prepare the 
adduct, a 5-fold molar excess of N-ethylmaleimide (NEM) was added to GSH and left 
for 30 min. NEM and GSH were dissolved in PBS (pH 7.4), and the reaction gives a 
stoichiometric conversion to the adduct. In the same manner the glycine-labeled GSH-
NEM adduct was synthesized from commercially available glycine 1,2-13C, 15N-GSH. 
Labeled and unlabeled adducts were confirmed by mass spectrometry [99].  
 
3.2.1.1.3 Synthesis of 15N-8-oxodG  
The stable isotope labeled 8-oxodG was synthesized based on the method reported by 
Singh et al. [39]. A 1 mg/mL solution of 15N5-dG (>98% 
15N, Silantes, Germany) was 
dissolved in a Chelex-treated 20 mM sodium phosphate buffer, pH 7.0. Then, 
sequentially, copper II sulphate, sodium ascorbate, hydrogen peroxide (final 
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concentrations 1.2, 170, and 370 mM, respectively) were added to the above solution 
and the reaction mixture incubated at ambient temperature for 20 min. The reaction was 
terminated by addition of 300 μL, 1mg/mL catalase. 15N5-8-oxodG was identified based 
on mass spectrometry and comparison of the retention time with authentic unlabelled 
standard. Isotopically labelled 8-oxodG was purified on a HPLC-UV (245nm), using a 
Hypersil ODS (250mm × 4. 6mm; 5μm, Phenomenex) column. The mobile phase was 
10% methanol in water, the total run time was 15 min at the rate of 1mL flow per minute. 
The retention times were 9.5 and 12.5 for 15N5-dG and 
15N5-8-oxodG, respectively. 
Purified 15N5-8-oxodG was confirmed by mass spectrometry. The pooled fractions were 
dried on centrifugal vacuum evaporator and reconstituted in water. Finally, the 
concentration was determined by using a calibration curve with unlabelled standard 8-
oxodG. 
 
3.2.1.2  Identification of fragmentation pattern for the analytes by 
mass spectrometry  
All the analytes and respective internal standards were individually dissolved in 10 % 
methanol in 0.1% formic acid. The analytes were manually tuned/scanned for the 
fragmentation pattern in both, positive and negative mode. From the manual tune, the 
base peak was identified, then the quantitative mass transitions were identified using 
Analyst 1.4.2 software. 
3.2.1.3  Separation of the analytes by LC and detection by ESI-
MS/MS 
20 μl of standards/sample were injected onto a reversed phase column Reprosil Pur 
ODS, 150 x 2.0 mm, 3 μm (Maisch, Ammerbuch, Germany). The gradient method with 
solvent A containing 0.1% formic acid in water and solvent B containing 100% methanol 
used a flow rate of  250μL/min. The total run time was divided into two periods. First 25 
min of positive mode was applied for detection. Second, from 25 min until the end of the 
run, the negative mode was used for detection (Table 1). 
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Table 1: The gradient method for the LC-ESI-MS/MS analysis   
Step 
 
Total Time 
(min) 
Flow Rate 
(μl/min) 
Solvent A (%) 
0.1% formic acid in 
water 
Solvent B (%) 
100% MeOH 
0 0 250 90 10 
1 10 250 80 20 
2 30 250 10 90 
3 35 250 90 10 
4 60 250 90 10 
3.2.1.4  Alternative method with 25 min run time 
In order to reduce the run time of the analysis, the gradient method was modified as 
given below (Table 2). By this method creatinine, GSSG, GSH, dG, 8-nitroG, 8-oxodG, 
can be separated and quantified. The other three markers Ang II, Aldo and 8-isoPGF2α 
cannot be analyzed. Moreover, only a positive mode mass spectrometry detection is 
possible. 
Table 2: The gradient method for 25min LC-ESI-MS/MS analysis   
Step 
 
Total Time 
(min) 
Flow Rate 
(μl/min) 
Solvent A (%) 
0.1% formic acid in 
water 
Solvent B (%) 
100% MeOH 
0 0 250 90 10 
1 10 250 80 20 
2 11 250 50 50 
3 13 250 50 50 
4 15 250 90 10 
5 25 250 90 10 
 
3.2.1.5  Validation of the method 
The validation of the method was carried out according to the Food and Drug 
Administration (FDA) and ICH guidelines for bio-analytical method validation. So the 
linearity, accuracy, precision, LOD, LOQ and recovery were determined for the new LC-
ESI-MS/MS method [100].  
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3.2.1.5.1 Linearity 
The linearity was checked with various concentrations of the standard solution. For 
preparation of the stock solution, the calculated amount of all the analytes was mixed 
into one stock.  From the stock solution a further serial dilution 1:1 ratio with mobile 
phase (10%MeoH in 0.1% formic acid) was performed to get the lowest concentration 
(Table 3). All the concentrations were mentioned in pmol, and the injection volume was 
20μL. 
 
Table 3: Concentrations of standard for linearity assesment  
s.no Creatinine 
(pmol) 
GSSG 
(pmol) 
dG 
(pmol) 
8-nitroG 
(pmol) 
8-oxodG 
(pmol) 
GSH-
NEM 
(pmol) 
Ang II 
(pmol) 
Aldo 
(pmol) 
8-
isoPGF2a 
(pmol) 
1 5000.00 100.00 45.00 1060.00 21.20 500.00 20.00 10.00 10.00 
2 2500.00 50.00 22.50 530.00 10.60 250.00 10.00 5.00 5.00 
3 1250.00 25.00 11.25 265.00 5.30 125.00 5.00 2.50 2.50 
4 625.00 12.50 5.63 132.50 2.65 62.50 2.50 1.25 1.25 
5 312.50 6.25 2.81 66.25 1.33 31.25 1.25 0.625000 0.625000 
6 156.25 3.13 1.41 33.13 0.662500 15.63 0.625000 0.312500 0.312500 
7 78.13 1.56 0.703125 16.56 0.331250 7.81 0.312500 0.156250 0.156250 
8 39.06 0.781250 0.351563 8.28 0.165625 3.91 0.156250 0.078125 0.078125 
9 19.53 0.390625 0.175781 4.14 0.082813 1.95 0.078125 0.039063 0.039063 
10 9.77 0.195313 0.087891 2.07 0.041406 0.976563 0.039063 0.019531 0.019531 
11 4.88 0.097656 0.043945 1.04 0.020703 0.488281 0.019531 0.009766 0.009766 
12 2.44 0.048828 0.021973 0.517578 0.010352 0.244141 0.009766 0.004883 0.004883 
13 1.22 0.024414 0.010986 0.258789 0.005176 0.122070 0.004883 0.002441 0.002441 
14 0.610352 0.012207 0.005493 0.129395 0.002588 0.061035 0.002441 0.001221 0.001221 
15 0.305176 0.006104 0.002747 0.064697 0.001294 0.030518 0.001221 0.000610 0.000610 
16 0.152588 0.003052 0.001373 0.032349 0.000647 0.015259 0.000610 0.000305 0.000305 
17 0.076294 0.001526 0.000687 0.016174 0.000323 0.007629 0.000305 0.000153 0.000153 
18 0.038147 0.000763 0.000343 0.008087 0.000162 0.003815 0.000153 0.000076 0.000076 
19 0.019073 0.000381 0.000172 0.004044 0.000081 0.001907 0.000076 0.000038 0.000038 
20 0.009537 0.000191 0.000086 0.002022 0.000040 0.000954 0.000038 0.000019 0.000019 
21 0.004768 0.000095 0.000043 0.001011 0.000020 0.000477 0.000019 0.000010 0.000010 
22 0.002384 0.000048 0.000021 0.000505 0.000010 0.000238 0.000010 0.000005 0.000005 
23 0.001192 0.000024 0.000011 0.000253 0.000005 0.000119 0.000005 0.000002 0.000002 
24 0.000596 0.000012 0.000005 0.000126 0.000003 0.000060 0.000002 0.000001 0.000001 
25 0.000298 0.000006 0.000003 0.000063 0.000001 0.000030 0.000001 0.000001 0.000001 
26 0.000149 0.000003 0.000001 0.000032 0.000001 0.000015 0.000001 0.000000 0.000000 
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3.2.1.5.2 Accuracy  
Accuracy is determined by replication of the analysis of a known concentration of the 
analyte. Three different concentrations were used, and five determinations of each 
concentrations were analyzed. The percentages of the relative standard deviations 
(%RSD) were checked for the peak area of the respective analytes.   
3.2.1.5.3 Limit of quantification (LOQ) and limit of detection (LOD) 
To determine the LOQ, the lowest range of the linearity solutions was used. The signal 
to noise (S/N) ratio was checked using Analyst1.4.2 software. The S/N ratio should be 
more than 5. For determination of LOD, the LOQ solution was further diluted, injected 
using the same method and checked for detectable peaks. The S/N ratio should be 3-5 
for LOD. 
3.2.1.5.4 Recovery 
Recovery studies were carried out using samples with or without spiking of a known 
concentration of standards. The difference between spiked and non-spiked sample is 
the recovered amount. 
3.2.1.6  Urine sample preparation  
200 μL of urine sample were treated with 20 μL of 200 nM freshly prepared N-
ethylmaleimide. Then, a fixed amount of stable isotope labeled internal standard was 
added. The final concentration of the internal standards was 10pmol d3-creatinine, 
5pmol 13C-15N-GSSG, 67.5pmol 15N-dG, 2.82pmol 15N-8-oxodG, 10pmol 13C-15N-GSH-
NEM, 0.51pmol 15N-13C-Ang II, 0.8pmol d7-Aldosterone and 1. 12pmol d4-8-isoPGF2α 
per injection. The sample was incubated for 20 min and centrifuged at room 
temperature. The prepared sample solution was transferred into a HPLC vial. 25 μL of 
mobile phase (10% MeOH in 0.1% formic acid) was added and vortexed for a few 
seconds to mix and to remove the air bubbles. Aliquots of 20 μL were injected into the 
HPLC using an auto sampler. 
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3.2.1.7  Plasma sample preparation 
Plasma sample preparation was carried out using Waters C-18 solid phase extraction 
(SPE) cartridges, as previously described [101] with little modification. 300μL fresh 
plasma were treated with 30 μL of 200 mM freshly prepared N-ethylmaleimide (final 
concentration of 20 mM) [98, 99] and spiked with a fixed amount of stable isotope 
labeled internal standard mixture. Final concentrations of the internal standards per 
injection were four X 10pmol d3-creatinine, 5pmol 13C-15N-GSSG, 67.5pmol 15N-dG, 
2.82pmol 15N-8-oxodG, 10pmol 13C-15N-GSH-NEM, 0.51pmol 15N-13C-Ang II, 0.8pmol 
d7-Aldosterone and 1. 12pmol d4-8-isoPGF2α. The above solution was incubated for 20 
min. The sample solutions were applied to the Waters C18 SPE cartridge that had been 
preconditioned with 5 mL of methanol and 15 mL of HPLC water, respectively. After 
loading the sample, the cartridge was washed with 3 mL of HPLC water. Vacuum was 
applied to dry the column which helps to eliminate the water from the eluent. The 
analytes or markers were eluted from the cartridge using 10 ml of methanol. The 
column elutes were collected and dried under nitrogen gas. Finally, the dried samples 
were re-dissolved in 60μL of mobile phase, then centrifuged at 14000 rpm for 15 min at 
4°C and transferred to a HPLC sample vial for LC-MS/MS analyses. 
3.2.2 Analysis of 8-oxodG from DNA by LC-ESI-MS/MS 
3.2.2.1  DNA isolation  
The leukocyte layer was used for DNA isolation. The genomic DNA was isolated from 
animal tissues/cultured cells/ leukocyte using a minor modification of a recently 
developed protocol designed to minimize artefacts of DNA-oxidation during isolation 
(chaotropic protocol; [37, 43]. This protocol has also been adopted by the European 
Standards Committee on Oxidative DNA damage (ESCODD). Whole blood was 
centrifuged at 2500 x g for 10 min at room temperature, yielding three layers. The upper 
layer is plasma; the intermediate layer contains concentrated leukocytes; and the 
bottom layer consists of erythrocytes. The animal tissues/cultured cell/ leukocyte pellets 
were homogenized with 3 ml of buffer A (320 mmol/L sucrose, 5 mmol/L MgCl2, 10 
mmol/L Tris/HCl, pH 7.5, 0.1 mmol/L desferrioxamine, and 1% (v/v) Triton X-100). After 
homogenization, the sample was centrifuged at 1500g for 10 min. washed with 1.5 ml of 
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buffer A and centrifuged again (1500g for 10 min). A total of 600 μl of buffer B (10 
mmol/L Tris/HCl, pH 8, 5 mmol/L EDTA–Na2, 0.15 mmol/L desferrioxamine) and 35 μl 
of 10%(w/v) sodium dodecyl sulfate were added, and the sample was agitated 
vigorously. After 30 μl of RNase A (1 mg/ml) in RNase buffers (10 mmol/L Tris/HCl, pH 
7.4, 1 mmol/L EDTA, and 2.5 mmol/L DFO) and 8 μl of RNase T1 (1U/μl in RNase 
buffer) were added, the samples were incubated at 37 °C for 1 h to remove 
contaminating RNA from the DNA. Then, 30 μl of proteinase K (20 mg/ml) was added 
and the samples were incubated at 37 °C for 1 h. Subsequently, 1.2 ml of NaI solution 
(7.6 M NaI, 40 mmol/L Tris/HCl, pH 8.0, 20 mmol/L EDTA–Na2, 0.3 mmol/L 
desferrioxamine) and 2 ml of 2-propanol were added. The sample was gently shaken 
until the DNA had precipitated completely and then centrifuged at 5000g for 15 min. The 
DNA pellet was washed with 1 ml of 40% (v/v) 2-propanol. After centrifugation (5000g 
for 15 min) the DNA pellet was washed with 1 ml of 70% (v/v) ethanol. Finally, the DNA 
pellet was collected by centrifugation and dissolved in 0.1 mmol/L desferrioxamine 
overnight. DNA concentration was measured by the absorbance at 260 nm. Protein 
contamination was checked using the absorbance ratio A260/A280; an absorbance ratio 
over 1.6 was acceptable. 
3.2.2.2  Enzymatic hydrolysis of DNA 
DNA hydrolysis was performed as described by Chao et al.[43]. DNA samples (about 20 
µg) from human blood were spiked with 2.82 pmol of 15N5-8-oxodG and 84.3 pmol of 
15N5-dG. Then 10µL of 1 U/µL nuclease P1 (in 300 mmol/L sodium acetate and 1 
mmol/L ZnSO4, pH 5.3) was added to the DNA solutions and the DNA was incubated at 
37 °C for 2 h. Thereafter, 10 µL of 10× alkaline phosphatase buffer (500 mmol/L 
Tris/HCl, pH 8, 1 mmol/L EDTA) containing 0.2 µL of alkaline phosphatase was added 
and the incubation was continued at 37 °C for 2 h. Finally 10µL of 0.1 M HCl was added 
to neutralize the solution. The neutralized DNA hydrolysates were filtered through a cut-
off filter tube (Ultrafree 5000 NMWL, Millipore, Germany) and centrifuged at 4°C and 
7000×g for 45 min then measured by online LC–MS/MS. 
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3.2.2.3  Automated solid-phase extraction 
The detailed column switching operation method is schematically described elsewhere 
(Figure 19) [43, 102]. The column-switching system consisted of a switching valve (two-
position microelectric actuator; Valco) and an Inertsil, ODS-3 column (50mm × 4.6mm; 
5μm). 100 μL of prepared DNA sample was loaded on to the trap column using auto 
sampler (Agillent 1100 series) with the switching valve at position B. The loading and 
washing buffer, 0.1% formic acid in 5% (v/v) methanol at a flow rate of 1mL/min was 
delivered by quaternary pump (Agillent 1100 series). The trap column was run with 
loading buffer for 3.6 min, followed by the valco valve changing to position A to transfer 
into the LC system. At 5 min after injection, the valve was switched back to injection 
position B, and the trap column was washed using a mobile phase with linear gradient 
from 100% of 0.1% formic acid   in 5% (v/v) methanol to 100% of 0.1 % formic acid in 
50% methanol for 7 min. This was followed by 100% of 0.1% formic acid in 5% (v/v) 
methanol for 3 min equilibration of the trap column. The valco valve was controlled by 
analyst® software 1. 4. 2 (Applied Biosystems) and the total run time was 15 min. After 
3.6 min, the sample was automatically transferred onto a polyamine-II endcapped HPLC 
column (YMC; 150mm × 4.6mm, 5μm) entering from the opposite direction. The 
isocratic method was used to achieve the desired sample separation using 85% (v/v) 
methanol with 0.1% formic acid at a flow rate of 1mL/min. The eluted sample from the 
HPLC system was introduced into the turbo ion spray source of an API 3000 triple-
quadrupole mass spectrometer (Applied Biosystem), operating in the positive ion mode, 
using nitrogen as the nebulizing gas and with the turbo gas temperature set at 475 °C. 
The multiple reaction monitoring conditions were obtained for the fragmentation of 8-
oxodG (284 to 168 m/z), 15N5-8-oxodG (289 to 173 m/z), 2‟-dG (268 to 152 m/z), and 
15N5-2‟-dG (273 to 157 m/z). Nebulizer and curtain gas flow rate were set at 12 arbitrary 
units. Collision assisted dissociation gas and turbo gas were set at 4 arbitrary units for 
both. The collision energy was set at 17eV and 21eV for dG and 8-oxodG respectively, 
nitrogen used as a collision gas. The separated 8-oxodG and dG were quantified using 
the respective internal standard (Figure 20). 
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Figure 19:  Schematic configuration and valve positions of the on-line extraction LC-MS/ 
MS system. (a) Sample loading position and (b) sample back flush and elution position. 
Modified schematic diagram with permission from Brink et al. [102](copyright 2006, Elsevier 
Limited). 
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Figure 20: LC-MS/MS chromatogram for analysis of 8-oxodG from DNA 
 
3.2.3 Total glutathione measurement by spectrophotometer 
dl-Buthionine-sulfoximine (BSO) (500 μM) was added for 24 h to achieve 
partial glutathione-depletion and thus enhance cellular sensitivity. Test substances were 
then added for 3 h. After incubation, cells were washed twice with PBS and 
resuspended in 400 μl 1% sulfosalicylic acid. After 15 min incubation on ice, cells were 
centrifuged (5000 × g). 20 μl of the supernatant was mixed with 260 μl of 
100 mM phosphate buffer, 20 μl of 2.5 mM dithiobis-2-nitrobenzoic acid and 
300 μl glutathione reductase (1.3 units glutathione reductase/ml, 50 mM phosphate 
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buffer, 0.5 mM EDTA, 0.3 mM NADPH) solution. The kinetics was determined at 
410 nm using a U-2000 Spectrophotometer (Hitachi, Tokyo, Japan) [67]. 
3.2.4 Ferric Reducing -Ability of Plasma/ -Antioxidant Power- (FRAP) Assay  
This method determines the reduction of a ferric tripyridyltriazine complex to its ferrous, 
coloured form, in the presence of plasma antioxidants. The antioxidative capacity of 
plasma/substances were determined as described by [103]. Briefly, 20µl of 
plasma/sample (which had been stored at -20°C) were added to 180 µl of water. Next, 
600 µl of the FRAP reagent was added and a photometric reading at 593 nm was taken 
immediately (data not shown), after 15min and after 30 min (not shown). The FRAP 
reagent consists of a 1:1:10 mixture of 10 mmol/L ferric-tripyridyltriazine, 20 mmol/L 
ferric chloride and 300 mmol/L acetate buffer. Three determinations from each sample 
were made at each time point. Results are given as ferric tripyridyltriazine complex 
reduction equivalents (µmol/L) [104]. 
 
3.3 Biological methods  
3.3.1 Superoxide measurement 
2x105 cells were seeded on coverslips the day before treatment. After the end of the 
treatment the medium was removed and cells were washed twice with PBS. Fresh 
medium was added containing 5 μM dihydroethidium (Merck Biosciences GmbH) and 
the cells were incubated for 30 min at room temperature in the dark. After washing with 
PBS, pictures of the cells were taken using an Eclipse 55i microscope (Nikon GmbH) 
and a Fluoro Pro MP 5000 camera (Intas Science Imaging Instruments GmbH) at 200-
fold magnification. Quantification was done by measuring grey values of 200 cells per 
treatment with ImageJ (http://rsb.info.nih.gov/ij/)[105]. 
3.3.2 Comet assay  
The isolated mouse kidney was minced to small pieces in 3 mL buffer [RPMI 1640, 15% 
DMSO, 1.8% (w/v) NaCl], filtered through a cell strainer with a mesh pore size of 100 
µm (Becton Dickinson), precipitated at 1,000 rpm and 4°C for 5 min (Heraeus Labofuge  
400e),  and re-suspended in 1 mL buffer. In the case of LLC-PK1 cells (3.5 ×105), they 
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were seeded the day before in small culture flasks, treated for 4 h with test substances 
in 5 mL medium then harvested. Isolated kidney cells or LLC-PK1 cells (20µL) were 
suspended in 180µL of low-melting-point agarose (0.5% diluted in calcium and 
magnesium-free PBS), and 45 µL of the suspension was embedded on the frosted 
microscope slides coated with a layer of high-melting-point agarose (1.5%, diluted in 
calcium and magnesium-free PBS). For lysis, slides were immersed in a jar containing 
fresh cold lysing solution (1% Triton X-100, 10% DMSO, and 89% lysis buffer containing 
10 mM Tris, pH 10; 1% Na-sarcosine; 2.5 M NaCl; and 100 mM Na2EDTA) and 
incubated at 4°C in a dark chamber for 1 h. Next, slides were placed into a horizontal 
electrophoresis tank with fresh alkaline electrophoresis buffer (300 mM NaOH and 1 
mM Na2-EDTA, pH 13), and left for 20 min at 4°C in the dark, to allow DNA unwinding 
and alkali-labile damage expression. Electrophoresis was carried out, at 4°C in the dark, 
for 20 min in a 25-V and 300-mA electrical field. Afterward, the slides were neutralized 
for 5 min in 0.4 M Tris (pH 7.5) and then the DNA was stained by adding 20 µL of 20 
µg/mL propidium iodide (CAS Nr. 25535-16-4) to each slide. A fluorescence microscope 
at ×200 and a computer-aided image analysis system (Komet 5; Kinetic Imaging, 
Bromborough, UK) was used for analysis. Fifty cells in total were analyzed; the mean 
tail DNA (percentage of intensity in the tail region) is given [106-108]. 
3.3.3 Microncleus frequency assay 
Micronuclei (MN) are expressed in dividing cells that either contain chromosome breaks 
(resulting from unrepaired double-strand breaks) and/or by whole chromosomes that 
are unable to travel to the spindle poles during mitosis. They are observed in cells with 
completed nuclear division and are scored in the binucleated stage of the cell cycle by 
using the cytokinesis inhibitor, cytochalasin B. The micronucleus frequency test was 
performed as described earlier [107, 109]. Cells were incubated for 4 h with the tested 
compounds, then 3 μg/ml cytochalasin B was added for 24 h to obtain binucleated (BN) 
cells. The frequency of micronuclei was obtained after scoring 1000 BN cells on each of 
two slides at a 400-fold magnification. 
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3.3.4 RNA isolation and semi quantitative reverse transcriptase PCR 
Total RNA was isolated from treated cells with the RNeasy mini kit (Qiagen, Hilden, 
Germany) and 2.5 µg of RNA was used for cDNA synthesis using RevertAidTM First 
Strand cDNA Synthesis Kit (Fermentas GmbH, St. Leon-Rot, Germany). cDNA was 
amplified by polymerase chain reaction (PCR) using REDTaqTM ReadyMixTM PCR 
Reaction Mix (Sigma-Aldrich, Taufkirchen, Germany) for 35-40 cycles using the primers 
depicted further down.  
The following primers with the respective GenBank accession number and predicted 
size were used for amplification: β-actin (NM_001101; 591 bp) 5‟-
TCCCTGGAGAAGAGCTACGA- 3‟ (sense), 5‟-GTCACCTTCACCGTTCCAGT-3‟ 
(antisense); glutathione peroxidase (GPX, NM_000581; 538 
bp) 5‟-CCAGTCGGTGTATGCCTT-CT-3‟(sense), 5‟-GATGTCAGGCTCGATGTCAA-3‟ 
(antisense); glutathione reductase (GR, NM_00637; 453) 5‟-
GATCCCAAGCCCACAATAGA-3‟ (sense), 5‟-CAGGCAGTCAACATCTGGAA-
3‟(antisense); glutathione synthase (GSS, NM_00-0178; 494 bp) 5‟-
CAGCGTGCCATAGAGAATGA-3‟ (sense), 5‟-TTCAGGGC-CTGTACCATTTC-3‟ 
(antisense). PCR products were resolved on a 1.5% agarose gel, stained with ethidium 
bromide. Results were related to the β-actin and subsequently normalised to the control. 
For quantification of the mRNA, the density of the bands was measured using Gel Doc 
2000 with the software Multi-Analyst Version 1.0.2 (Bio-Rad, Hercules, CA, USA) [67]. 
 
3.3.5 Statistics  
Mann-Whitney test was used to determine significance between two groups and 
Kruskal-Wallis test was used to determine significance between multiple groups 
(GraphPad InStat 3.05 software). Values are given as means ±  standard error mean 
(SEM) or as means ± standard deviation (SD). A p value ≤0.05 was considered 
statistically significant. 
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4 Results  
4.1 LC-ESI-MS/MS method development and validation: Analysis of 8-
oxodG, 8-isoPGF2α, 8-nitroG, GSH, GSSG, dG, angiotensin II, 
aldosterone, and creatinine within a single run. 
4.1.1 Synthesis of stable isotope labeled internal standards 
4.1.1.1 Synthesis of 15N-13C-GSSG 
After synthesis the pure 15N-13C-GSSG was isolated using a HPLC-UV method (Figure 
21-22). The synthesized glycine-labeled GSSG was scanned in the positive mode mass 
spectrometry in the range of 100 to 1000 m/z and the molecular ion was observed at 
619. 20H+ and the product ions were 361 and 490 m/z.     
                                 
                   
 
 
Figure 21) Chemical reaction of labeled GSSG from labeled GSH. A solution of 2mM labeled 
GSH was treated with an equal volume of 16mM hydrogen peroxide. The reaction was carried 
out at 25°C for 6h 
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Figure 22: 13C-15N-GSSG was isolated using HPLC-UV with a Reprosil pur (150 x4.6 mm; 
5μm), column with a mobile phase of 10% MeOH in 0.1% TFA. The isocratic run time was 15 
min and the flow rate 400μL/min, the analytes were detected at 210nm. HPLC-UV 
chromatogram of B) GSSG standard peak, C) Reaction mixture peaks, D) Pure isolated 15N-
13C-GSSG peak.  
 
4.1.1.2  Synthesis of 15N-13C-GSH-NEM 
GSH was detected as the GSH-NEM adduct. In order to prevent the artifactual oxidation 
of GSH to GSSG during sample preparation, it is very important to block the thiol group 
of GSH with NEM. Furthermore the NEM adduct is more easily detectable by positive 
electro spray ionization [99]. The synthesized labeled GSH-NEM adducts showed 
molecular ion at 436 m/z and product ion at 307 m/z mass spectrometer. 
 
4.1.1.3  Synthesis of 15N-8-oxodG  
Figure 23 shows a typical chromatogram obtained when an aliquot of the reaction was 
separated by semi preparative HPLC. The identity of the peak corresponding to 15N5-8-
oxodG was confirmed by LC/MS analysis. Contamination due to the peak from 15N5-dG 
was detected. To remove this contamination, the 15N5-8-oxodG fraction was re-injected 
onto the HPLC system. The concentration of 15N5-8-oxodG was determined by UV 
C  
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spectrometry. The purified 15N5-8-oxodG (Figure 24), which is five mass higher than that 
of unlabelled standard was confirmed by mass spectrometry (Figure 25). 
 
Figure 23: HPLC-UV chromatogram for the reaction mixture for synthesis of 15N5-8-oxodG from 
15N5-dG 
-  
Figure 24: HPLC-UV chromatogram for the purified 15N5-8-oxodG from 
15N5-dG reaction mixture 
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Figure 25: Mass fragmentation of 15N5-8-oxodG (the asterisks indicate the labeled sites in the 
internal standard) in positive mode. The MS/MS spectrum for 15N5-8-oxodG is shown 
corresponding to the product ion for 15N5-8-oxoG at m/z 173 formed from the [M+H]
+ ion at m/z 
289.  
4.1.2 Mass spectrometer parameters 
 
A triple-stage quadrupole mass spectrometer (API 3000, Applied Biosystems, 
Darmstadt, Germany) equipped with a Turbo Ionspray source was used. The ion spray 
voltage was 3500 V, the source temperature 400°C. The analytes were monitored in the 
positive and negative multiple reaction monitoring (MRM) mode simultaneously. For 
optimum sensitivity, specific product ions and optimal instrument settings were obtained 
by infusion of authentic standards and using the quantitative optimization function of the 
Analyst 1.4.2 software (Applied Biosystems, Darmstadt, Germany). Table 4 provides the 
details of the instrumental settings. Two transitions for each analytes were monitored. 
Peak areas of the most sensitive transitions were used for quantification. Creatinine, 
GSSG, GSH-NEM, dG, 8-nitroG, 8-oxodG and Ang II were analyzed using positive 
MRM mode. Aldosterone and 8-isoPGF2α were analyzed using negative MRM mode.  
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Table 4. Multiple reaction monitoring parameters for the analytes. 
 
Analytes 
 
Precursor 
ion 
 Q1 
 
 
Product ion 
Q3 
DP FP CE CXP 
Creatinine  114 44* 16 90 17 15 
  86 16 90 17 15 
d3-creatinine  117 89* 16 90 17 15 
GSSG 613.20 335.16* 20 200 30 15 
  484 16 130 5 24 
13C-15N-GSSG 619.20 361.16* 20 200 30 15 
  490 20 200 30 15 
dG 268.20 152.10* 16 90 17 14 
15N-dG 273.20 157.10* 16 90 17 14 
8-nitroG 197.23 151.00 86 300 21 16 
8-oxodG 284 168* 21 110 21 16 
15N-8-oxodG 289 173* 21 110 21 16 
GSH-NEM 433.31 304.09* 20 200 30 15 
  201.10 20 200 30 15 
13C-15N-GSH-NEM 436 307* 20 200 30 15 
Ang II 523.95 263.10* 41 210 31 26 
  110.10 41 210 57 10 
15N-13C-Ang II 528.84 273.20* 61 150 31 24 
  110.20 61 150 61 18 
Aldo 359.28 188.80* -56 -
220 
-26 -9 
  331 -56 -
220 
-24 -19 
d7-Aldo 366.15 192.80* -61 -
220 
-28 -9 
  338 -61 -
220 
-24 -17 
8-isoPGF2α 353 193.05* -61 -
220 
-36 -17 
  273 -61 -
220 
-30 -17 
d4-8-isoPGF2α 357 197* -20 -
220 
-30 -15 
*Transitions used for quantification 
DP: declustering potential [V]; FP: focusing potential [V]; CE: collision energy 
[V]; CXP: collision cell exit potential [V]. 
 
 
4.1.3 Separation of analytes by LC and detection by ESI-MS/MS 
To achieve the final separation method of these compounds took numerous trials. 
Reduced flow rates and the selection of the appropriate mobile-phase composition are 
key factors for high sensitivity in LC-ESI-MS, because the ion formation process in ESI 
involves the ionization of sample molecules in the liquid phase. In general, a solvent 
Positive mode 
detection 
Negative mode 
detection 
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with low surface tension, low viscosity, and low heat of vaporization would increase the 
production of gas-phase ions. For those reasons, ESI measurements usually employ 
acidified solutions of acetonitrile (ACN)/water or methanol (MeOH)/water. A study 
reported that MeOH as the organic modifier represents a better mobile-phase system 
for nano LC-ESI-MS/MS, especially analysis of peptide mixtures [110]. Moreover, 
methanol is less expensive and less toxic than ACN, therefore, we used methanol as an 
organic modifier in our method.  
We used a simple mobile phase consisting of 0.1% formic acid in water and 100% 
methanol. The gradient started with 10% methanol and increased 2% per min until 10 
min. In this period creatinine, GSSG, dG and 8-nitroG were separated. After 10 min 
methanol was increased up to 3.5% per min until 30 min to separate GSH-NEM, 8-
oxodG and Ang II. When the gradient contained about 65% methanol, Ang II eluted. 
After 30 min the methanol amount was reversed to 10% until the end of the run at 60 
min (Figure 26 - 32).          
 
 
Figure 26: Total ion chromatogram for the analyzed markers were detected using positive and 
negative mode. 
Time, min 
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Figure 27: Multiple reaction monitoring (MRM) chromatograms for individual analytes (Positive 
mode) 
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Figure 28: Multiple reaction monitoring (MRM) chromatograms for individual analytes (negative 
mode) 
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Figure 29: Multiple reaction monitoring (MRM) chromatograms from a representative sample of 
WT young mice (12-13 weeks) showing urinary analytes and respective stable isotope internal 
standards (Positive mode) 
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Figure 30: Multiple reaction monitoring (MRM) chromatograms from a representative sample of 
WT young mice (12-13 weeks) showing urinary analytes and respective stable isotope internal 
standards (negative mode). 
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Figure 31: Multiple reaction monitoring (MRM) chromatograms from a representative sample of 
WT young mice (12-13 weeks) showing plasma analytes and respective stable isotope internal 
standards (positive mode).  
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Figure 32: Multiple reaction monitoring (MRM) chromatograms from a representative sample of 
WT young mice (12-13 weeks) showing plasma analytes and respective stable isotope internal 
standards (negative mode). 
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4.1.4 Method validation  
The method was validated according to the U.S. Department of Health and Human 
Services, Food and Drug Administration guidelines for bioanalytical method [100]. The 
limit of quantification (LOQ) was defined as the lowest concentration of analytes that 
could be reliably and reproducibly measured for accuracy, intraday precision, and 
interday imprecision. The determined LOQs were 9.7 pmol for creatinine, 0.04pmol for 
8-oxodG, 0.24pmol for GSH-NEM, 6.2 pmol for GSSG, and for 8-isoPGF2α less than 
0.01pmol. Ang II and aldosterone yielded less than 0.01pmol on the column. The limit of 
detection (LOD), defined as the lowest concentration that gave a signal-to-noise ratio of 
at least 3, was found to show acceptable values for all analytes (Table 5). The linearity 
of the analytes was not less than 0.977, which is acceptable according to the FDA 
guidelines.  
 
Table 5: Linearity, LOQ, LOD and recovery for the analytes. 
Markers  Linearity r 
=  
LOQ 
pmol  
LOD pmol (S/N)  Recovery in % 
Lower 
range 
Higher 
range 
Creatinine  0.9987  9.7  2.5 (3.9)    
8-oxodG  0.9917  0.04  0.01 (3)    
GSH-NEM  0.9954  0.24  0.0076 (4)  46.005 33.731 
GSSG  0.9779  6.2  6.2 (14.5)  113.83 102.7175 
Ang II  0.9904  0.0012  0.0000048 (12.5)  103 93.2875 
Aldo  0.9875  0.0048  0.00015 (13.5)    
8-isoPGF2α  0.9899  0.0012  0.0000024 (186)  107.75 71.775 
 
The accuracy of the method was checked with low, middle and high concentration of the 
analytes standards and the % relative standard deviations (%RSD) were calculated. 
The accuracy was also checked for the method variation using a run time of 25 min. 
The % RSDs for all analytes and both methods were within the acceptable limit (Table 
6).  
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Table 6: Listed markers in two different methods 
Markers  Accuracy 60 min run time % rsd  Accuracy 25 min run time % rsd  
 low  middle  High  low  middle  High  
Crea  7.31  4.92  2.01  2.55  4.40  3.83  
8-oxodG  4.34  2.75  1.72  3.33  1.63  0.93  
GSH-NEM  7.45  8.31  3.79  6.38  3.24  5.43  
Ang II  6.21  3.80  2.34  8.51  8.42  5.14  
Aldo  6.53  4.92  5.25     
8-isoPGF2α  14.26  6.44  7.89     
 
In the following parts of this thesis is, this optimized method was applied for the analysis 
of urine samples from WT and p47phox-/- mice. 8-oxodG, Ang II, aldosterone, and 8-
isoPGF2α were quantified. GSSG and GSH were detected but not quantified, because 
these markers have no biological relevant in urine.  8-nitroG was not detectable and dG 
was not considered in these samples (refer to section 4.2).  
Furthermore, plasma samples from WT and p47phox-/- mice were analyzed. GSSG and 
GSH, Ang II, Aldosterone and 8-isoPGF2α were quantified. dG, 8-oxodG and 8-nitroG 
were not detected (refer to section 4.2). 
 
4.2 Role of the NOX subunit p47phox on oxidative DNA and lipid 
damage 
4.2.1 Role of p47phox in the formation of oxidative DNA damage  
To investigate whether p47phox is necessary for ROS induced oxidative DNA damage 
during ageing, we compared young and old WT and p47phox -/- mice. The level of DNA 
damage determined by comet assay analysis in the liver and kidney is shown in figure 
33 A and B. There was no statistically significant difference between young WT and 
p47phox-/- mice. However, in kidneys from old mice there was a significant difference 
between the groups (Figure 33 A and B). The DNA damage in the kidneys from old WT 
animals was about three fold higher than in young WT mice. The difference in livers 
from WT and p47phox -/- mice was not significant (Figure 33 B), but showed a trend for 
elevated damage in WT mice. 
  Results 
 
55 
 
To characterize further the DNA damage, we analyzed the oxidative DNA base 
modification 8-oxodG, from kidney DNA of young and old WT versus p47phox-/- mice. 
The level of 8-oxodG is expressed as adducts per millions of dG. There was an 
accumulation of 8-oxodG in kidney with age in WT but not in p47phox-/- mice (Figure 
34). And there were statistically significant differences between WT and p47phox-/- 
mice with WT mice showing more 8-oxodG in both age groups.  
 
 
 
 
Figure 33: DNA damage measured by the comet assay A) mouse kidney cells from WTY (n=6, 
female, 21-23 weeks),  p47phox-/-Y (n=5, female, 21-23 weeks), WTO (n=9, 5 male, 4 female, 
52-53 weeks), p47phox-/-O (n=4, female, 30 weeks); B) mouse liver cells from WTY (n=6, 
female, 21-23 weeks),  p47phox-/-Y (n=5, female, 21-23 weeks), WTO (n=9, 5 male, 4 female, 
A 
B 
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52-53 weeks), p47phox-/-O (n=4, female, 30 weeks); n= number of samples analyzed; WTY= 
wild type young; WTO= wild type old; p47phox-/-Y= p47phox knockout mice young; p47phox-/-O= 
p47phox knockout mice old. Values are expressed in mean ± SE; P≤ 0.05 considered 
significant.    
 
 
Figure 34: Oxidative modification of DNA by LC-MS/MS. 8-oxodG from mouse kidney WTY 
(n=6, female, 21-23 weeks),  p47phox-/-Y (n=5, female, 21-23 weeks), WTO (n=9, 5 male, 4 
female, 52-53 weeks), p47phox-/-O (n=4, female, 30 weeks); n= number of samples analyzed; 
WTY= wild type young; WTO= wild type old; p47phox-/-Y= p47phox knockout mice young; 
p47phox-/-O= p47phox knockout mice old. Values are expressed in mean ± SE; P≤ 0.05 
considered significant.  
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Figure 35: Oxidative modification of DNA by LC-MS/MS. A) mouse urinary 8-
oxodG/creatinin(nmol/μmol) from WTY (n=6, female, 12-13 weeks),  p47phox-/-Y (n=6, female, 
12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-O (n=2, female, 30 
weeks); B) mouse urinary 8-oxodG/L from WTY (n=6, female, 12-13 weeks),  p47phox-/-Y (n=6, 
female, 12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-O (n=2, female, 
30 weeks). n= number of samples analyzed; each urine sample contains cumulated two animals 
urine. WTY= wild type young; WTO= wild type old; p47phox-/-Y= p47phox knockout mice young; 
p47phox-/-O= p47phox knockout mice old. Values are expressed in mean ± SE; P≤ 0.05 
considered significant. 
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We also analyzed the urinary 8-oxodG in young and old WT and p47phox-/- mice. 
Urinary 8oxodG measurement has received considerable attention as a biomarker of 
oxidative genomic damage. This adduct enables noninvasive sample gathering and it is, 
extremely stable in this matrix [111]. For accurate quantification of the urinary lesion, the 
newly developed LC-ESI-MS/MS method was used for simultaneous quantification of 
urinary 8-oxodG and creatinine for normalization. Significant differences were observed 
between WT and p47phox-/- mice in both age groups with WT mice showing higher 
values than phox mice (Figure 35 A and B). And there was a significant difference in 
young and old WT urinary 8-oxodG normalized with creatinine (Figure 35A).   
     
4.2.2 Role of p47phox in the formation of lipid peroxidation products 
Isoprostanes are a series of prostaglandin-like compounds produced by non-enzymatic 
peroxidation of arachidonic acid [112]. 8-iso-prostaglandin F2α is an indicator of lipid 
oxidation by free radicals and recognized as an excellent biomarker for oxidative stress 
damage [113]. Moreover, 8-isoPGF2α is stable and relatively abundant in biological 
fluids including plasma, urine and tissues as well as in lipid-rich foods [114]. 
 
We analyzed the urinary and plasma 8-isoPGF2α from young and old WT and p47phox-
/- mice (Figure 36 and 37). The level of urinary 8-isoPGF2α/creatinine showed a 
significant difference between WT and p47phox-/- in the aged group (WT higher than 
p47phox-/- mice)(Figure 36), but not in the young group. Moreover, values were twenty 
fold higher in aged WT mice compared to young WT (Figure 36). The 8-isoPGF2α level 
in plasma showed a clear difference between WT and p47phox-/- mice in the old group. 
The level was significantly higher in old WT than young WT mice (Figure 37A). 
However, we did no see any difference in the young group.  
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Figure 36: The oxidative lipid damage marker 8-isoPGF2α measured using LC-ESI-MS/MS in 
urine . Mouse urinary 8-isoPGF2α/creatinin (nmol/μmol) from WTY (n=6, female, 12-13 weeks),  
p47phox-/-Y (n=6, female, 12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-
O (n=2, female, 30 weeks); n= number of samples analyzed; each urine sample contains 
cumulated two animals urine. WTY= wild type young; WTO= wild type old; p47phox-/-Y= p47phox 
knockout mice young; p47phox-/-O= p47phox knockout mice old. Values are expressed in mean ± 
SE; P≤ 0.05 considered significant. 
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Figure 37: The oxidative lipid damage marker 8-isoPGF2α measured using LC-ESI-MS/MS in 
plasma. A) mouse plasma 8-isoPGF2α from WTY (n=4, female, 21-23 weeks),  p47phox-/-Y 
(n=3, female, 21-23 weeks), WTO (n=6, female, 52-53 weeks), p47phox-/-O (n=3, female, 30 
weeks); B) mouse urinary 8-isoPGF2α/L from WTY (n=6, female, 12-13 weeks),  p47phox-/-Y 
(n=6, female, 12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-O (n=2, 
female, 30 weeks). n= number of samples analyzed; each urine sample contains cumulated two 
animals urine, each plasma sample contains plasma of two or more animals to achieve a 
volume which was sufficient for analysis. WTY= wild type young; WTO= wild type old; p47phox-/-
Y= p47phox knockout mice young; p47phox-/-O= p47phox knockout mice old. Values are 
expressed in mean ± SE; P≤ 0.05 considered significant. 
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4.2.3 Influence of p47phox on oxidation of glutathione  
An important oxidative stress marker is oxidized form of glutathione (GSSG). The 
increased ratio of GSSG/GSH indicates oxidative stress.  To find the influence of 
p47phox on glutathione oxidation, we analyzed the GSSG and GSH level in plasma 
from young and old WT and p47phox-/-mice. The GSSG/GSH ratio was significantly 
higher in WT mice than p47phox-/- mice in both the age groups (Figure 38). However, no 
difference in young and aged mice was seen in WT or p47phox-/- mice.    
 
Figure 38: Mouse plasma GSSG/GSH ratio from WTY (n=4, female, 21-23 weeks),p47phox-/-Y 
(n=3, female, 21-23 weeks), WTO (n=6, female, 52-53 weeks), p47phox-/-O (n=3, female, 30 
weeks); n= number of samples analyzed; each plasma sample contains plasma of two or more 
animals to achieve a volume which was sufficient for analysis. WTY= wild type young; WTO= 
wild type old; p47phox-/-Y= p47phox knockout mice young; p47phox-/-O= p47phox knockout 
mice old. Values are expressed in mean ± SE; P≤ 0.05 considered significant. 
4.2.4 Is angiotensin II a key player in ageing? 
The Renin-Angiotensin-Aldosterone-system (RAAS), is involved in the regulation of 
blood pressure and vasoconstriction. Binding of Ang II to its AT1 receptor and 
aldosterone via mineralocarticoid receptor mediates the generation of free radicals via 
NOX and that contributes damage to the tissues [65, 96, 106, 115, 116]. We were 
interested to study the role of p47phox in Ang II induced DNA and lipid damage during 
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ageing. Therefore we analyzed Ang II and related hormone Aldosterone from urine and 
plasma (Figure 39-43). The amount of urinary Ang II and aldosterone was about four 
and five fold higher in old than in young WT mice (Figure 39 A and 40A). Also level of 
Ang II showed a significant difference between WT and p47phox-/- mice in both young 
age groups but not in old. There was a significant correlation between the Ang II and the 
oxidative DNA damage marker urinary 8-oxodG as well as the oxidative lipid damage 8-
isoPGF2α (Figure 41A and 42A). Aldosterone also showed a significant correlation 
between both oxidative DNA (Figure 41 B) and lipid damage (Figure 42B). However, the 
plasma concentration of Ang II and Aldosterone showed no significant difference 
between the groups.  
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Figure 39: Ang II was analysed from urine and plasma by LC-ESI-MS/MS. A) mouse urinary 
Ang II/creatinin(pmol/μmol) from WTY (n=6, female, 12-13 weeks),  p47phox-/-Y (n=6, female, 
12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-O (n=2, female, 30 
weeks); B) mouse urinary Ang II/L from WTY (n=6, female, 12-13 weeks),  p47phox-/-Y (n=6, 
female, 12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-O (n=2, female, 
30 weeks); n= number of samples analyzed; each urine sample contains cumulated two animals 
urine. WTY= wild type young; WTO= wild type old; p47phox-/-Y= p47phox knockout mice young; 
p47phox-/-O= p47phox knockout mice old. Values are expressed in mean ± SE; P≤ 0.05 
considered significant. 
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Figure 40: Aldosterone was analysed from urine and plasma by LC-ESI-MS/MS. A) mouse 
urinary aldosterone/creatinin(pmol/μmol) from WTY (n=6, female, 12-13 weeks),  p47phox-/-Y 
(n=6, female, 12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-O (n=2, 
female, 30 weeks); B) mouse urinary aldosterone/L from WTY (n=6, female, 12-13 weeks),  
p47phox-/-Y (n=6, female, 12-13 weeks), WTO (n=4, 2 male, 2 female, 52-53 weeks), p47phox-/-
O (n=2, female, 30 weeks);   n= number of samples analyzed; each urine sample contains 
cumulated two animals urine. WTY= wild type young; WTO= wild type old; p47phox-/-Y= p47phox 
knockout mice young; p47phox-/-O= p47phox knockout mice old. Values are expressed in mean ± 
SE; P≤ 0.05 considered significant. 
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Figure 41: A) Correlation between urinary Ang II vs urinary 8-oxodG. B) Correlation between 
urinary aldosterone vs urinary 8-oxodG C) Correlation between urinary 8-isoPGF2α vs urinary 
8-oxodG (p values from spearman rank correlation coefficient) P≤ 0.05 considered significant  
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Figure 42: A) Correlation between urinary Ang II vs 8-isoPGF2α. B) Correlation between 
urinary aldosterone vs 8-isoPGF2α (p values from spearman rank correlation coefficient; P≤ 
0.05 considered significant 
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Figure 43: A) Mouse plasma Ang II from WTY (n=4, female, 21-23 weeks),  p47phox-/-Y (n=3, 
female, 21-23 weeks), WTO (n=6, female, 52-53 weeks), p47phox-/-O (n=3, female, 30 weeks); 
B) Mouse plasma aldosterone from WTY (n=4, female, 21-23 weeks),  p47phox-/-Y (n=3, 
female, 21-23 weeks), WTO (n=6, female, 52-53 weeks), p47phox-/-O (n=3, female, 30 weeks);  
n= number of samples analyzed; each plasma sample contains plasma of two or more animals 
to achieve a volume which was sufficient for analysis. WTY= wild type young; WTO= wild type 
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old; p47phox-/-Y= p47phox knockout mice young; p47phox-/-O= p47phox knockout mice old. 
Values are expressed in mean ± SE; P≤ 0.05 considered significant. 
 
Recently, we reported that Ang II induced oxidative stress and DNA damage in the pig 
kidney cell line LLC-PK1 [109]. Therefore, we studied the role of p47phox in Ang II 
induced DNA damage. DNA strand breaks were quantified using the comet assay in 
isolated kidney cells of young and old WT and p47phox-/- mice after Ang II treatment 
(200nM, 30min, in vitro incubation). We found a significant level of DNA damage in Ang 
II treated cells of WT compared with untreated cells (Figure 45), but no differences in 
cells from p47phox-/- mice. 
 
 
Figure 45: DNA damage measured by the comet assay in cell isolates from kidney and treated 
with or without 200nM Ang II. Mouse kidney cells from WTY (n=6, female, 21-23 weeks), 
p47phox-/-Y (n=3, female, 21-23 weeks), WTO (n=6, 5 male, 4 female, 52-53 weeks), p47phox-/-
O (n=4, female, 30 weeks); n= number of samples analyzed; WTY= wild type young; WTO= wild 
type old; p47phox-/-Y= p47phox knockout mice young; p47phox-/-O= p47phox knockout mice old. 
Values are expressed in mean ± SE; P≤ 0.05 considered significant. 
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4.3 Rosuvastatin prevents angiotensin II–induced genotoxicity 
4.3.1 Rosuvastatin prevents angiotensin II-induced superoxide formation 
Superoxide formation can be observed with the superoxide sensitive dye 
dihydroethidium in LLC-PK1 cells after treatment with angiotensin II (Ang II) (Figure 45 
A and B). This induction is significantly decreased after co-incubation with 1 µM 
rosuvastatin. 
   
 
Figure 45: Formation of superoxide anions by angiotensin II (AngII) and its prevention by 
rosuvastatin. A) Dihydroethidium reacts with the superoxide radical anion and produces the 
fluorescent 2-hydroxyethidium. 1 µM Rosuvastatin (RSV) protects LLC-PK1 cells from the 
Control 200nM Ang II 200nM Ang II + 1μM 
RSV 
A 
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superoxide anion radicals produced by Ang II; B) Quantification of the amount of superoxide 
anions (gray scale units). The experiment was done a single time, and 50cells were counted. 
4.3.2 Rosuvastatin prevents angiotensin II-induced genomic damage 
Ang II causes DNA strand breaks in LLC-PK1 cell dose dependently (Figure 46A). 
Rosuvastatin was able to prevent the genotoxicity of Ang II in LLC-PK1 cells. The DNA 
strand breaks, measures by the comet assay were significantly reduced already by 10 
nM rosuvastatin (Figure 46B). No further reduction could be observed with the higher 
rosuvastatin concentration of 1 µM. Ang II causes micronuclei (subtype of chromosomal 
aberration) in LLC-PK1 cell dose dependently (Figure 47A). The frequency of 
micronuclei was also lowered significantly by rosuvastatin (Figure 47B). The putative 
mutagenic DNA base modification 8-oxodG, formed in cells incubated with Ang II, was 
quantified by LC-MS/MS (Figure 48). There was a dose dependent increase of 8-
oxodG. Rosuvastatin was able to prevent the formation of this DNA lesion.  
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Figure 46: Rosuvastatin (RSV) prevents Ang II induced DNA damage. A) Ang II induced DNA 
damage monitored with the comet assay. LLC-PK1 cells were treated with Ang II in different 
concentrations and the percentage of DNA in tail was measured; B) Rosuvastatin (RSV) 
protects LLC-PK1 cells from DNA strand breaks caused by Ang II; Values are expressed in 
mean ± SD; P≤ 0.05 considered significant 
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Figure 47: Rosuvastatin (RSV) prevents Ang II induced genomic damage. A) Micronucleus 
induction by Ang II in LLC-PK1cells, single time experiment and two slides were counted; B) 
Rosuvastatin (RSV) protects LLC-PK1 cells from micronuclei formation. Cells were treated with 
Ang II with/ without 1µM RSV for 4h, then cytochalasin B was added and incubated for 24 h. 
The micronucleus frequency was determined in binucleated cells. Values are expressed in 
mean ± SD; P≤ 0.05 considered significant 
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Figure 48: Rosuvastatin (RSV) prevents Ang II induced genomic damage. A) Ang II induced 8-
oxodG in LLC-PK1 cells dose-dependently, which was analyzed by Isotope diluted LC-MS/MS 
method. Rosuvastatin protects LLC-PK1 cells from oxidative DNA damage caused by Ang II.  
Values are expressed in mean ± SD; P≤ 0.05 considered significant 
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4.3.3 Rosuvastatin increases glutathione levels and glutathione 
metabolising enzymes 
The measurement of the total glutathione levels in LLC-PK 1 cells revealed the potential 
of rosuvastatin to increase the amount of this important redox state regulating molecule. 
Together with Ang II, which alone also induced a significant rise of the cellular 
glutathione amount, rosuvastatin showed a synergistic effect on glutathione levels. 
Compared to the control neither rosuvastatin nor Ang II were able to increase the 
cellular glutathione amount. When utilised together, the two substances provoked a 
significant rise of glutathione levels (Figure 49A). 
Analysis of the expression of three genes involved in glutathione metabolism, 
glutathione synthase, glutathione reductase and glutathione peroxidase (Figure 49B), 
showed that they are all upregulated in LLC-PK1 cells incubated with rosuvastatin alone 
(Figure 49B). No significant upregulation could be detected in cells treated either with 
angiotensin II alone or with the combination of Ang II and rosuvastatin. 
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Figure 49: Rosuvastatin (RSV) increases glutathione and its metabolizing enzymes A) Total 
glutathione were analyzed in LLC-PK1 cells to check the protective effect of RSV against Ang II 
B 
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B) Glutathione metabolic enzyme gene expression. GSS= glutathione synthetase; GR= 
glutathione reductase; GPX= glutathione peroxydase; BSO= dl-Buthionine-sulfoximine.         
4.3.4 Rosuvastatin exerts its DNA-damage preventive effects independent 
of HMG-CoA reductase inhibition 
To assess the impact of HMG-CoA reductase inhibition on the observed protective 
effects of rosuvastatin, intermediates of the cholesterol synthesis pathway were tested 
for their ability to reverse rosuvastatins actions. In the case of a HMG-CoA reductase 
inhibition-dependent effect, the effect would be reversed by a pathway intermediate. 
Since the addition of neither farnesol (FOH), farnesyl pyrophosphate (FPP) nor 
geranylgeraniol (GGOH) led to a significant increase of DNA damage again (Figure 50), 
the independence of rosuvastatins DNA damage preventive effect of HMG-CoA 
reductase inhibition was shown. 
 
Figure 50: Rosuvastatin (RSV) protects LLC-PK1 cells from Ang II induced DNA damage 
independent of cholesterol sysnthesis. RSV=rosuvastatin; FOH=farnesol; FPP= farnesol 
pyrophosphate; GGOH= geranylgeraniol. 
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4.4 Parkinson’s disease and oxidative DNA damage 
Demographic and clinical data of the subjects enrolled in this study are presented in 
Table 7. The mean age of the control group was 68.8±4.9 and that of PD patients was 
71.2± 3.2 years. All PD patients were treated with L-DOPA (188 – 1850 mg/day; Table 
8) plus dopa decarboxylase inhibitor, either carbidopa (25 – 425 mg/day) or 
benserazide (47 – 187 mg/day) or both (142.18 – 462.5 mg/day). Nine PD patients also 
received the COMT inhibitor entacapone (600 – 1200 mg/day; Table 8). Nine patients 
were treated with a combination with the dopamine agonists pramipexol (1 – 3 mg/day), 
bromocriptin (8 mg/day) or piribedil (50 mg/day), the NMDA-antagonists amantadine 
(100mg/day) or budipin (10mg/day) or a combination within these classes of drugs 
(Table 8). Some patients were additionally treated with the monoamino oxidase B 
(MAO-B) inhibitors selegiline (10mg/day) or rasagiline (1mg/day), or the antipsychotic 
drugs quetiapin (25 – 250 mg/day) or clozapin (44mg/day; Table 8). Eleven patients 
also received other medications such as anti-diabetics, antihypertensive or thyroid 
management pharmaceuticals (Table 7). Like the PD patients, 7 out of 12 individuals of 
the control group suffered from typical health problems for this age group and took 
appropriate medications (Table 7). Gender distribution was unequal between the 
groups, with more females in the control group because they were life partners of the 
male PD patients. There was one smoker in each group and few individuals listed the 
intakes of antioxidant supplements.  
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Table 7: Characteristics of study participants 
 PD patients Control  
Number of  participant 18 12 
Sex (male/female) 12/6 1/11 
Smokers/non-smokers 1/17 1/11 
Age at study (years)range 71.2 ± 3.2 (65-78) 68.8±4.9 (61-80) 
Age at onset (years) range 61.0 ± 7.8(47-77) Not applicable 
Daily dose of L-Dopa (mg/day) 
range 
808.68 ± 476.11 
(188-1850) 
Not applicable 
Duration of Treatment (years) 
range ( L-DOPA consumption) 
9.8±5.2 (1.0 – 20) Not applicable 
Anti-oxidants/vitamin 
supplementation intake (yes/no) 
3/16 2/10 
Other medications (anti 
diabetics; antihypertensive; 
thyroid management; etc.) 
(yes/no) 
11/8 7/5 
The table with permission from Oli. R. G. et al. [104](copyright 2010, Springer). 
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Table 8: Anti-Parkinson‟s disease therapy 
 Combination therapy for PD patients No of  PD 
L-DOPA (1200mg/day) + dopa decarboxylase inhibitor (300mg/day) 3 
L-DOPA (600mg/day)+ dopa decarboxylase inhibitor ( 150mg/day) + COMT 
inhibitor (1000 mg/day) 
2 
L-DOPA ( 587.5mg/day)  + dopa decarboxylase inhibitor (110.15 mg/day)  + 
dopamine agonist ( 20.10mg/day) 
3 
L-DOPA ( 850mg/day)  + dopa decarboxylase inhibitor ( 212.48mg/day)  
+antipsychotic (50mg/day) 
1 
L-DOPA ( 775mg/day)  + dopa decarboxylase inhibitor ( 193.75mg/day)  + 
COMT  inhibitor ( 950mg/day)  + dopamine agonist (2 mg/day) 
4 
L-DOPA ( 975mg/day)  + dopa decarboxylase inhibitor (182.81 mg/day)  + 
COMT inhibitor (800mg/day)  +antipsychotic (106.25 mg/day) 
3 
L-DOPA (559.375mg/day)  + dopa decarboxylase inhibitor (117.38mg/day)  
+ MAO B inhibitors ( 5.5mg/day)  + dopamine agonist (34.85 mg/day) 
2 
The table with permission from Oli. R. G. et al. [104](copyright 2010, Springer). 
We analyzed the 8-oxodG in lymphocyte DNA and detected significantly elevated levels 
of this oxidative DNA-alteration in PD patients compared to the control group (Figure 
51A). In the presence of elevated DNA-oxidization an increased amount of oxidative 
stress and a decreased antioxidative defense might be expected. Therefore, the 
antioxidant capacity of the plasma (FRAP-capacity) was determined (Figure 51 B). 
However, the FRAP values were significantly higher in PD patients than in controls. To 
investigate the biological consequences of the elevated DNA-oxidization we analyzed 
the micronucleus frequency in lymphocytes, but found no difference between the groups 
[104].  
The daily dose of L-DOPA (188 - 1850 mg/day) correlated significantly with FRAP 
values in the plasma of PD patients (data not shown). When we analysed the 
antioxidant power of L-DOPA and dopamine in vitro in the FRAP assay, we found 
strong antioxidant capacities for both compounds in the cell free system (data not 
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shown). When we compared the biomarkers values (Figure 52A), treated without (9 
patients) / with (9 patients) dopamine agonist within L-DOPA treated PD patients, the 
treatment with-dopamine agonist group showed positive correlations with 8-oxodG 
(Figure 52C), and MN (data not shown). After treatment of the neuronal cell line PC12 
with 100 µM dopamine for 2 hours, we isolated the cellular DNA and measured the 8-
oxodG content, which was elevated significantly (data not shown). 
 
 
 
 
 
 
 
 
 
Figure 51: A). Oxidative stress biomarker 8-oxo-7,8-dihydro-2‟-deoxyguanosine (8-oxodG) in 
peripheral lymphocyte DNA of healthy individuals and Parkinson disease (PD) patients after 
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chronic L-DOPA treatment. Shown are in box-plot with median values.  B). Antioxidant capacity 
of plasma (Ferric Reducing Ability of Plasma- (FRAP) -Assay; µmol/L equivalents) of healthy 
individuals and PD patients after chronic L-DOPA treatment. Shown are in box-plot with median 
values. The figure with permission from Oli. R. G. et al. [104](copyright 2010, Springer). 
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Figure 52: Oxidative stress biomarker 8-oxo-7,8-dihydro-2‟-deoxyguanosine (8-oxodG) in 
peripheral lymphocyte DNA of Parkinson disease (PD) patients after chronic L-DOPA treatment 
without and with dopamine agonist .  A). Shown are group averages with standard deviations. 
B). Correlation of the 8-oxodG and L-DOPA daily dose in without dopamine agonist therapy. C). 
Correlation of the 8-oxodG and L-DOPA daily dose in with dopamine agonist therapy. The figure 
with permission from Oli. R. G. et al. [104](copyright 2010, Springer). 
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5 Discussion 
The increased oxidative stress causes DNA damage which leads to altered genomic 
information. As one pathway for increased ROS production, many endogenous (eg. 
angiotensin II (Ang II), aldosterone) and exogenous substances activate NADPH 
oxidase (NOX) enzyme and produce ROS (superoxide anion radicals, hydrogen 
peroxide, hydroxyl radicals). Rosuvastatin is a lipid lowering drug and shows pleotropic 
effect including antioxidant effect. Moreover, rosuvastatin reduces elevated level of 
angiotensin II type 1 receptor (AT1R), oxidative stress and protects the vascular 
system. Commonly, the oxidative stress is elevated in ageing and age related diseases 
(eg. Parkinson‟s disease (PD)). The oxidative stress and oxidative DNA damage was 
analyzed using newly developed isotope-diluted-LC-ESI-MS/MS methods.   
 
5.1 Method development and validation: Analysis of oxidative stress 
markers and other analytes by LC-ESI-MS/MS 
LC–MS/MS has proven one of the most effective tools in biochemical research. 
Particularly it is very useful for quantifying small amounts in complex biological matrices. 
LC–MS/MS based methods are generally characterized by high specificity, sensitivity 
and high-throughput potential [117]. The use of electrospray ionization (ESI) coupled 
with a triple quadrupole mass spectrometer [118] has already emerged as a powerful 
analytical tool in clinical biochemical genetics [119]. Several methods are available to 
measure 8-oxodG, 8-isoPGF2α, reduced and oxidized glutathione, dG, 8-nitroG, Ang II, 
aldosterone and creatinine in urine and plasma. But in our newly developed LC-ESI-
MS/MS method we were able to measure all the analytes within a single run. This 
method was validated by us for C57BL/6J mouse urine and plasma samples. Most 
probably the method is applicable to samples from other animals and human samples.  
Concerning urinary 8-oxodG analysis, there are several methods available [47, 120-
125]. Recently the European Standards Committee for Urinary (DNA) Lesion Analysis 
(ESCULA; http://www.escula.org) was established to answer the issues associated with 
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the analysis of urinary DNA biomarkers of oxidative stress [46, 111, 126].  Many reports 
suggest that the commercially available 8-oxodG ELISA kits correlates with 
chromatographic techniques. It is an easier alternative to gold-standard techniques such 
as HPLC-ECD or LC-MS/MS. On the other hand, analysis of 8-oxodG by ELISA shows 
more variation within the technique than chromatography [111]. 
The new method shows a LOQ of 0.04pmol and a LOD of 0.01 pmol on the column with 
signal to noise ratio of >3 for 8-oxodG. The linearity was r=0.9917 and the accuracy in 
the low, middle and higher concentration range was within limits of the FDA guideline 
for both the 60 min and the 25 min method variations. With the satisfactory validation 
report, the analytical method was applied to analyze the markers from mouse urine and 
plasma for finding a possible role of p47phox in NOX derived DNA damage during 
aging. 
A recently published method with simultaneous analysis of dG and 8-oxodG from 
cellular DNA using LC-MS/MS technique [43] prevented artifact formation of 8-oxodG 
during analysis by using online solid phase sample extraction. However, the resolution 
between 8-oxodG (RT: 7.4 min) and dG (RT: 7.8) was small. After analysis of a few 
samples the resolution became even smaller. Therefore, the artifact 8-oxodG peak 
appeared closer or merged with the original peak, which may often lead to wrong 
interpretation of the data. With our newly developed method the resolution between dG 
and 8-oxodG was more than 4 min. Probably the above discussed issue could be 
solved by replacing the analytical column and mobile phase, but without changing the 
extraction column. 
Creatinine is a breakdown product of creatinine phosphate, and the amount depends on 
the muscle tissue in the body and the renal function. The creatinine rate of excretion is 
relatively constant over time. Therefore, most of the urinary markers are commonly 
normalized to creatinine [60]. Recently, the analysis of creatinine and urinary 8-oxodG 
was described in two different variations [60]. However, due to the limited urine volume 
from mice, it is very difficult to analyze creatinine by conventional calorimetric methods 
and it is time consuming to do the analysis of 8-oxodG and creatinine in two different 
methods. Therefore, we developed a simultaneous analysis of creatinine and 8-oxodG 
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together with other analytes. To the best of our knowledge this is the first report for 
simultaneous analysis of creatinine and 8-oxodG using a stable isotope dilution LC-ESI-
MS/MS method.   
 
Quantification of 8-isoPGF2α has been suggested as a reliable indicator of lipid 
peroxidation [54, 127]. There are several advantages of 8-iso-PGF2α analysis because 
of its chemical stability, its specific product during lipid oxidation, and because the levels 
are unaffected by diet, and there are quantitatively sufficient amounts for detection in 
the biological fluids such as  plasma [128], serum [129] and urine [54, 128, 130, 131]. 
There are several traditional methods available for analysis of 8-isoPGF2α including 
ELISA and RIA. Chromatographic methods such as gas chromatographic (GC), or liquid 
chromatographic methods are also available; GC has high sensitivity and specificity but 
sample preparation is extensive [132-134].  
 
Recently developed LC-MS/MS methods have a very good sensitivity, with LOQ of 
5pg/ml and a LOD of 1pg/ml [135, 136]. With our newly developed simultaneous 
analysis of 8-iso-PGF2α and creatinine the LOQ was 1.2 fmol and less than 1 fmol for 
LOD on the column. This may be due to the gradient method and the mobile phase 
which we use in our method. The 8-iso-PGF2α elutes at about 30 min, at that time the 
gradient is about 90% methanol and 10% formic acid water. The organic modifier 
methanol increased the ESI performance significantly. Fortunately, 8-iso-PGF2α has a 
relatively high lipophilic nature; therefore, larger amounts of organic solvent were used 
for separation, which resulted in good sensitivity. The recovery of the analyte showed 
107% and 71.77% for the lower and higher concentration range, respectively. 
Concerning accuracy, the %RSD is 14.2 for the low range, which is a bit higher than the 
recommended limit, but the middle and higher range were within the limit, and the 
method showed very good linearity. The newly developed stable isotope dilution LC-
ESI-MS/MS method had very good sensitivity and enabled simultaneous analysis with 
creatinine for urinary 8-iso-PGF2α calculation. The method was applied to measure 
urinary and plasma 8-iso-PGF2α from WT and p47phox -/- mice. 
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GSH is the most abundant intracellular thiol molecule and plays an essential role in 
maintaining the redox environment. It exists in millimolar (1-10mM) concentrations in 
most cell types. On the other hand, the plasma concentration is in the micromolar 
range, which is approximately 0.4% of total blood GSH. The molar GSH: GSSG ratio 
exceeds 100:1, this ratio has been reported to decrease to values between 10:1 and 
even 1:1 in various disease models of oxidative stress [119, 137]. The measured 
concentrations of GSH and GSSG are highly variable among different reports [138-146]. 
Accurate measurement of reduced and oxidized glutathione from biological fluids is still 
very challenging because of the rapid oxidation of GSH to GSSG. Many sample 
preparation methods are used for determination of GSH in the biological samples, 
including deproteinization, derivatization and reduction. 
Usually the protein precipitation has been carried out by acidification using 
trichloroacetic acid (TCA), perchloric acid, metaphosphoric acid, or sulfosalicylic acid, 
which yields a clear, protein-free supernatant after centrifugation. TCA is the a very 
useful protein precipitating agent and, about 3-4%  oxidation of GSH occurs during 
sample preparation [147]. 10% Metaphosphoric acid yields about 1-2% GSH oxidation 
at 4°C for at least 24h [148]. However, the above mentioned reagents alone cannot 
eliminate the autoxidation of GSH.  Chemical protection of the thiol group is necessary 
to prevent the GSH oxidation completely.  This may be achieved by alkylating SH 
groups by addition of N-ethylmaleimide (NEM) which is a strong and fast alkylation 
agent (Figure 53). 
 
 
Figure 53: Protection of GSH form autoxidation by alkaylation at the SH group with N-
ethylmaleimide (NEM).   
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Our sample preparation method, assures almost 100% protection of GSH from 
autoxidation by the use of the excess NEM. Therefore, the protected GSH and true 
GSSG of the sample can be extracted with solid phase extraction and quantified by LC-
ESI-MS/MS technique. It is important that NEM is added immediately after collection of 
the samples (eg, whole blood or plasma) and that storage is done at -80°C until sample 
preparation for LC-ESI-MS/MS analysis. 
Analysis of GSH and GSSG is possible with different methods, including 
spectrophotometer, HPLC-UV, HPLC-FL, HPLC-ECD, GC-MS, LC-MS, and LC-MS/MS. 
LC-MS has more advantages than all other methods because of ion suppression, ion 
enhancement matrix effect, and the use of stable isotope internal standards for accurate 
quantification. LC-MS is a powerful technique for the analysis of low-molecular thiols, 
including GSH [149]. Many groups published the simultaneous analysis of thiols and 
disulfides using LC-MS/MS methods [48,98,99,100] and recently  Zhang et al reported a 
LC-MS/MS method for the analysis of GSH and GSSG in cultured cells treated with 
diethyl maleate (DEM), a GSH depleting agent [150]. Our newly developed LC-ESI-
MS/MS method also has the advantage of simultaneous analysis of GSH and GSSG, 
with satisfactory recovery, accuracy and linearity. Moreover, by this method we 
separated diastereomers of the GSH-NEM adduct which appeared at 10.33 and 11.88 
min. The separation pattern was similar to a recently reported one [151]. 
Various methods have been used for analysis of Ang II, including HPLC combined with 
radioimmunoassay [152-154]. The radioimmunoassay relies on specific antibodies for 
each peptide. Recently, LC-MS, LC-MS/MS [101] and nano-LC-MS [155, 156] methods 
have been developed for analysis of Ang II and related peptides in biological fluids. The 
above mentioned method has good accuracy and sensitivity. However, none of the 
methods used Ang II labeled internal standard for accurate quantification and to identify 
the specific Ang II peak in the complex biological samples. Therefore, in our LC-ESI-
MS/MS method we used 15N-13C-Ang II which is ten mass higher than Ang II, as an 
internal standard. The  mass transition 523.95 m/z [M+2H]2+ as a precursor ion and 
263.10 m/z as product ion in the multiple reaction monitoring mode was employed for 
quantification of Ang II  [155]. LOD for Ang II was less than 1fmol on column. Accuracy, 
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recovery and linearity of the method were satisfactory. In the sample collection or 
preparation step, we recommend to use a peptidase inhibitor (sodium metabisulfite, 
phosphoramidon, and thiorphan, final concentrations, 5mM, 0.1mM, and 10µM 
respectively) pre-coated tube for blood/urine collection [157] or a tube containing 50µL 
of 0.5M EDTA, 50µL of 0.5 M captopril (ACEi), trypsin inhibitor (0.15mg/mL blood) and 
aporotinin (2µg/mL blood). Both peptidase inhibitors are described to prevent 
degradation of peptides [109]. However, in our present study, we were not aware of the 
reagents at the time of sample collection. Therefore we could not use either reagent, but 
we recommend their use for further applications.     
Accurate measurement of Ang II and Aldosterone concentrations may be essential for 
correct diagnosis of an elevated renin-angiotensin- aldosterone system. Therefore, our 
new method has the advantage of simultaneous analysis of Ang II and aldosterone in 
urine and plasma. There are many methods that can determine the aldosterone 
concentration in biological samples, including radioimmunoassay [158, 159], 
chemiluminescence-immunoassay [160, 161], GC-MS [162-164], LC-MS/MS [165-167] 
and LC-ESI-MS/MS [168]. The LC-MS/MS method provides a more reliable 
measurement of aldosterone than immunoassay and GC-MS and is becoming 
increasingly used in the clinical setting [167]. Our method has less than 1 fmol LOD and 
acceptable linearity for aldosterone. Both aldosterone and the internal standard d7-
aldosterone were detected using negative mode ionization and quantified in the multiple 
reaction monitoring mode with following transitions 359.28 to 188.80 m/z and 366.15 to 
192.80 m/z, respectively.  
To the best of our knowledge, this is the first study where simultaneous analysis of 8-
oxodG, 8-isoPGF2α, GSH and GSSG, dG, 8-nitroG, Ang II, aldosterone and creatinine 
were performed within a single run. The method is applicable to oxidative stress related 
pre-clinical, clinical, and basic research fields. In plasma, GSH, GSSH, 8-isoPGF2α, 
Ang II, aldosterone and creatine are quantifiable, where 8-oxodG, 8-nitroG and dG are 
not detected. In urine, 8-oxodG, GSH, GSSH, 8-isoPGF2α, Ang II, aldosterone, creatine 
and dG are quantifiable. But GSH, GSSG, and dG are not biological relevant and 8-
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nitroG was not detectable amount in our study. In tissues, probably all the analytes are 
biological relevant and quantifiable.        
 
5.2 Role of p47phox in Nox derived oxidative DNA and lipid damage  
We applied the newly developed LC-ESI-MS/MS method to determine the amount of 8-
oxodG, 8-isoPGF2α, GSH, GSSG, AngII, aldosterone, and creatinine in WT and 
p47phox-/- mice in different age groups.  
In this study, we found that the oxidative DNA adducts 8-oxodG and the lipid oxidation 
product 8-isoPGF2α increasing with aged in WT mice, but not in p47phox-/- mice. Most 
probably the NOX derived ROS played an important role. To the best of our knowledge 
we report for the first time that the NOX organizer subunit p47phox plays a critical role 
in the formation of the mutagenic marker 8-oxodG.     
A recent review describes the kidneys as very susceptible to damage by ageing, 
including morphological and functional changes [169]. We saw that DNA strand breaks 
were increased in kidneys of old WT mice compared with young WT. Also, strand 
breaks showed a clear difference appeared between old WT and p47phox-/- mice, and a 
slight but not significant difference in young kidneys. 8-oxodG was elevated in animal 
organs at older age in various animal models, including mice and rats. However, only 
few studies were able to achieve a background level of 8-oxodG within the limit of 
ESCODD values in which there is no artifact formation during analysis [23]. Our 
background value of about 3 adducts per 106 dG was within the range of ESCODD 
suggested values. The 8-oxodG level from young and old WT kidney DNA showed a 
significant difference and about 40% increased mean value with ageing.  
Recently, Mikkelsen et. al., found an age dependent accumulation of 8-oxodG in WT 
mouse liver DNA analyzed by a chromatographic method, but no difference was 
observed in DNA strand breaks analyzed by comet assay [22]. We analyzed the DNA 
strand breaks in WT and p47phox-/- mouse liver in the young and old age group. There 
was a slightly elevated damage in old WT liver compared to p47phox-/-. The background 
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damage in liver was about 50% less than in kidney. We saw a clear significant 
difference in old kidneys but only a small one in liver tissues. Ang II may activate NOX 
[170] and therefore, a relatively high amount of damage may be caused in the kidney 
where the renin-angiotensin-aldosterone system (RAAS) is locally involved with a 
relatively larger amount of Ang II [65]. Interestingly also the urinary 8-oxodG analyzed 
by LC-ESI-MS/MS was significantly higher in WT than p47phox-/- mice in both age 
groups. Some studies suggest that diet may manipulate the urinary 8-oxodG content 
[171-173], but ESCULA concluded that is not the case [47, 174-176]. Levels of urinary 
8-oxodG vary with the different analysis techniques. The recent ESCULA validation 
report suggests that chromatography based MS or ECD methods have less within-
technique-variation than ELISA [111]. Therefore the elevated urinary 8-oxodG in WT 
mice analyzed by LC-ESI-MS/MS can be considered to represent true oxidized lesion 
from p47phox dependent NOX derived ROS.  
It is always important to measure more than one oxidative biomarker to elucidate the 
influence of oxidative stress. F2-Isoprostanes are the major products of lipid oxidation 
produced by the reaction of free radicals. Among all the 64 diastereoisomers of 
isoprostane, 8-isoPGF2α received most attention because it is not only a biomarker of 
oxidative stress but is also involved in renal and pulmonary vasoconstriction, various 
pathological conditions and also in the normal physiology of aging [53]. Urinary and 
plasma 8-isoPGF2α analyzed by LC-ESI-MS/MS increased with age in WT mice but not 
in p47phox-/- mice. After normalization to urinary creatinine, we still found that WT mice 
excreted more 8-isoPGF2α than old p47phox-/- mice, but there was no difference in 
young mice despite a LOD of less than 1 fmol on the column. However, since we had 
seen a difference in 8-oxodG we believe that the basal level production of NOX derived 
ROS is not capable of oxidizing lipid molecules but is sufficient for oxidizing DNA, 
especially guanine. This idea is supported by a study reporting iron-catalyzed DNA and 
lipid oxidation in-vitro, which also concluded that the presence of a low amount of free 
radicals is enough to damage the DNA but not the lipid molecules [177].  
Another oxidative stress marker is oxidized glutathione. The analyzed GSSG/GSH ratio 
was significantly higher in WT than in p47phox-/- mice in both age groups. This was due 
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to elevated GSH in p47phox-/- mice rather than  decrease in GSSG. The reason may be 
that p47phox-/- mice use less of GSH for ROS inactivation than WT mice. The increased 
amount of 8-oxodG and 8-isoPGF2α in WT mice may thus correspond to elevated level 
of GSSG/GSH. 
Several reports suggest that Ang II activates NOX and produces ROS [61, 170]. Under 
normal physiological conditions, Ang II may regulate redox signaling pathways. 
However, overactivation of RAAS contributes to ageing [178-182] and age related 
diseases [183]. Therefore, we analyzed the urinary and plasma Ang II and aldosterone 
level by LC-ESI-MS/MS. We saw age dependent increases of urinary Ang II and 
aldosterone normalized to creatinine, supporting a RAAS contribution to ageing. It is not 
clear whether the plasma level of Ang II is age dependent but an age dependence has 
been reported for aldosterone. On the other hand, in the sample preparation we had 
neither added a general peptidase inhibitor nor selective ACE inhibitors to prevent the 
degradation of Ang II. This may also be the reason that we did not see an age 
dependent increase of Ang II in plasma. Interestingly, a study using 30 months saline 
treated rats showed an increased level of Ang II in cardiac tissue, but not in plasma. 
Probably the elevated level of Ang II in the cardiac tissues was due to the role of local 
RAAS involved in the heart [178]. To know more about the relation between Ang II and 
kidney ageing, one must analyze the Ang II content in WT mouse kidney in young and 
old groups, where we saw a significant elevation of the mutagenic DNA lesion 8-oxodG. 
The creatinine normalized Ang II and Aldosterone showed a significant positive 
correlation with urinary 8-oxodG and 8-isoPGF2α. Modlinger et al [184] reported that 
urinary 8-isoPGF2α was increased in Ang II infused rats suggesting that Ang II 
contributes to increased lipid oxidation, which happens probably through NOX derived 
ROS. Ang II not only causes damage to lipids but also to the DNA, [109, 185, 186], 
which is described in more detail in a recent review [65]. Even 1nM Ang II was able to 
cause significant DNA damage in the isolated perfused mouse kidney [106]. We see 
significant age dependent DNA strand breaks caused by 200 nM Ang II treatment in 
isolated cells of WT mice and slightly but not significantly higher damage in p47phox-/- 
detected by comet assay. Based on the above results we believe that Ang II may play a 
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crucial role in age dependent damage to DNA at least in the kidney. However, 
aldosterone induced age dependent DNA damage to kidney needs to be investigated. 
Recently, we reported that aldosterone causes DNA strand breaks in the pig kidney cell 
line LLC-PK1 at nanomolar concentrations, and desoxycorticosterone acetate-salt 
(DOCA-salt), an aldosterone precursor, induced 8-oxodG in rats [108]. Moreover,  we 
reported that aldosterone caused DNA strand breaks in immortalized mouse aortic 
endothelial WT cells (iMAEC with p47phox subunit) but not in iMAEC cells lacking 
p47phox (p47phox-/- cells) [65]. This suggests that Ang II and aldosterone probably 
influence the oxidative DNA damage and this action might be via NOX derived ROS.     
Overall, the NOX organizer protein p47phox plays a crucial role in the formation of the 
oxidatively modified mutagenic base 8-oxodG in the kidney. Probably this effect is 
intensified with the action of Ang II and aldosterone.      
  
5.3 Rosuvastatin protects angiotensin II–induced oxidative genomic 
damage  
Statins are commonly used cholesterol lowering agents, acting through inhibition of 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyses a rate 
limiting step in for cholesterol biosynthesis. Most of the statins including rosuvastatin 
have pleiotropic effects [187].  Among these, antioxidant properties of statins received 
much attention. It was hypothesized that statins protect from NOX induced ROS via 
upregulation of endogenous anti-oxidant enzymes [188].  Moreover, the antioxidant 
effect of statins appeared to be independent of cholesterol inhibition. Atorvastatin 
prevented the formation of Ang II induced free radicals in vascular smooth muscle cells 
by inhibiting Rac1 mediated NOX activity and down regulating AT1 receptor expression, 
both being independent of cholesterol inhibiting action [189]. Moreover, rosuvastatin 
protected DNA from oxidative stress in vitro [67, 109, 190], most probably via 
upregulation of glutathione sysnthesis [67].  
Ang II caused oxidative stress, DNA damage and chromosomal aberrations in LLC-PK1 
cells [109]. Ang II is an endogenous substance synthesized in the kidney and the 
  Discussion 
 
94 
 
elevated amount causes oxidative stress and related diseases. Therefore, we selected 
Ang II and the pig kidney cell line LLC-PK1 to study the protective effect of rosuvastatin 
on DNA damage. At 10 nM rosuvastatin prevented DNA strand breaks analyzed by 
comet assay and at 1µM it protected from chromosomal aberration measured by 
micronuclei frequency assay. Furthermore, we also analyzed the oxidative mutagenic 
marker 8-oxodG in cells treated with Ang II alone and combined with rosuvastatin by 
LC-MS/MS. 1µM rosuvastatin was able to protect the LLC-PK1 cells from elevated 
oxidative DNA damage. The protective effect of rosuvastatin acts probably via inhibiting 
the activation of NOX enzyme which contributes to the DNA base modification. Further 
experimental evidence is required to prove that rosuvastatin inhibits NOX activity and 
expression of AT1 receptor in Ang II induced oxidative stress and DNA damage. 
However, it was already demonstrated that rosuvastatin attenuates Ang II induced 
cardiomyocyte hypertrophy via inhibition of AT1 receptor [191]. The increased amount 
of total glutathione in Ang II and rosuvastatin treated cells supported the idea that the 
protective effect of rosuvastatin was achieved via the antioxidant effect. Rosuvastatin 
alone upregulates the expression of glutathione synthase, glutathione reductase and 
glutathione peroxidase in LLC-PK1 cells which we also observed in HL-60 cell line [67].  
The treatment of cells with cholesterol biosynthesis intermediates farnesol, farnesyl 
pyrophosphate, geranylgeraniol did not reverse the action of rosuvastatin. Therefore, 
rosuvastatin action was probably independent of cholesterol inhibition.    
Overall, rosuvastatin protected the cells from Ang II induced oxidative stress, DNA and 
genomic damage in vitro. The protective effect of rosuvastatin is achieved via 
upregulation of glutathione and it is independent of cholesterol biosynthesis inhibition.  
5.4 Parkinson’s disease and oxidative DNA damage 
In the present study, we demonstrated that the oxidative stress biomarker 8-oxodG was 
elevated in chronically L-DOPA-treated patients with PD, which agrees with previous 
reports using post-mortem brain tissue of PD patients [81, 82]. In our study the gender 
distribution was unequal between the groups, with more females in the control group 
because they were life partners of the male PD patients. While no data are available 
about a potential influence of gender on the 8-oxodG level in the DNA of peripheral 
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lymphocytes, we still cannot exclude a confounding effect of this gender difference, 
since reports stated that men excrete 29% [120] or 35% [122] more 8-oxodG than 
females in their urine, while others reported no differences [121, 123].  
Among the five normal nucleotide bases, guanine is the most susceptible to oxidation, 
particularly the C8 position of deoxyguanosine is most effectively oxidized by hydroxyl 
radicals [192, 193]. In PD, several studies have examined whether the disease process 
is associated with a higher production or a lower detoxification of oxidants. Increased 
ROS production has been observed in peripheral blood monocyte cells (PBMC) after 
treatment with L-DOPA plus other medications used in a combined therapy (Prigione et 
al. 2006). Cerebrospinal fluid and plasma from PD patients showed higher oxidative 
stress in the form of lipoprotein oxidation after treatment with L-DOPA and dopamine 
agonists [194]. Vitte et al described that oxidative stress significantly increased in 
neutrophils from L-DOPA treated PD patients, but the role of additional medications or 
the disease itself remained unclear [195]. Antioxidant effects of additional medications, 
i.e. dopamine agonists, may be involved in some of the observed effects.  Le et al 
reported that dopamine agonist showed antioxidant property independent of dopamine 
receptor activation [196]. Interestingly, a positive correlation was observed between 8-
oxodG or MN amount of dopamine agonist within the subgroup of L-DOPA treated PD 
patients also receiving a dopamine agonist.  This effect may be due to binding of D2 
receptor by dopamine agonist. The cell might then recruit more dopamine inside the cell 
by activation of dopamine transporters (DAT). Once dopamine is inside, MAO converts 
it to metabolites and ROS which leads to formation of 8-oxodG, which can be prevented 
by  the MAO inhibitor PCPA [104, 197]. 
Another endpoint for oxidative stress is the antioxidative capacity of plasma, measured 
as FRAP. Since low FRAP values indicate high oxidative stress or low antioxidant 
defense level, an inverse correlation with the levels of 8-oxodG might be expected. 
Instead, in our study the antioxidative capacity of plasma was higher in PD patients than 
in the control group. Elevated DNA oxidation should lead to increased genomic 
damage. However, micronucleus frequencies were not elevated compared to the 
controls. Opposite to that, Migliore et al reported an elevated micronucleus formation in 
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untreated PD patients [83]. A potential conclusion is that treatment with L-DOPA plus 
dopa decarboxylase inhibitors in our patients might have protected the patients from 
PD-related additional chromosomal damage. This assumption of a protective effect is 
supported by the correlation between antioxidant FRAP values and daily L-DOPA doses 
(plus dopa decarboxylase inhibitors). The dopa decarboxylase inhibitor carbidopa 
increases the plasma half-life of L-DOPA from 50 min to 80 min and decreases the 
plasma and urinary dopamine and its major metabolite homovanillic acid. When 
decarboxylation of L-DOPA is prevented by carbidopa, COMT becomes the major 
metabolizing enzyme for L-DOPA, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-
phenylalanine (3-OMD). When the COMT inhibitor entacapone is given together with L-
DOPA and carbidopa, plasma levels of L-DOPA are greater and more sustained than 
after administration of L-DOPA and carbidopa alone [104].  
Increased antioxidative capacity and no increase of micronuclei despite elevated 8-
oxodG may be interpreted as a protective effect of L-DOPA therapy on genomic 
integrity. Our findings of an antioxidative capacity of L-DOPA and dopamine in a cell 
free in vitro system suggest a potential direct antioxidative effect of L-DOPA (and the 
small quantities of dopamine that are formed) in the serum. In support of this idea, a 
recent study employing the comet assay (single cell gel electrophoresis) as measure for 
DNA-damage detected that L-DOPA treatment reduced the DNA damage in peripheral 
blood cells from patients with PD [104, 198].  
Peripheral blood lymphocytes express dopa decarboxylase (DDC) and L-type amino 
acid transporter (LAT1), and are able to uptake L-DOPA and convert it into dopamine. 
In addition, dopamine can enter via dopamine transporters (DAT) which has also been 
found on the lymphocyte plasma membrane [199-202]. Increased cytosolic levels of 
dopamine have been found to induce formation of ROS, and of semiquinones and 
quinones after catabolism and autooxidation [203]. In agreement with this, in our 
experiments with PC12 cells, dopamine caused oxidative stress leading to elevated 8-
oxodG. Thus, the observed elevated 8-oxodG in the peripheral lymphocytes may be 
due to activities of dopamine inside the lymphocytes. Dopamine has been described to 
induce genomic damage in V79 cells, in the presence of metals like manganese, 
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copper, iron and cobalt, which could be effectively prevented by reduced glutathione 
[204]. We recently reported that dopamine caused genotoxicity in the rat neuronal PC12 
cell, human lumpholastoid TK6 cells and rat kidney NRK cells, which was prevented by 
addition of antioxidants, dopamine type 2 receptor antagonists and DAT inhibitors [205]. 
Following chronic L-DOPA therapy, the amount of 8-oxodG formed in peripheral blood 
lymphocytes may be below a threshold for micronucleus induction, but it is not known 
whether it may result in an increased gene mutation frequency. In fact, dopamine has 
been described as mutagenic in a mammalian in vitro mutation assay [104, 206]. 
Major confounding factors for micronucleus frequency are generally age and gender. 
The age was not significantly different between groups here. Females are known to 
have higher frequencies than males [207]. Therefore, we cannot exclude that the 
micronucleus frequency would have been slightly elevated in the PD group, if gender 
distribution would have been equal. Antioxidant intake via supplements may influence 
the micronucleus frequency but was equal between patients and controls. Influences of 
other medications may be complex and are not well studied, but were similar between 
patients and controls [104].   
Overall, medication with L-DOPA may upon conversion to dopamine inside of peripheral 
lymphocytes or other cells contribute to the oxidative stress burden in PD patients by 
increasing the intracellular 8-oxodG formation. But at the same time L-DOPA enhances 
the antioxidant level in the serum, thus protecting PD patients from increased oxidative 
stress. Other medications may add to these effects, and as an overall consequence, the 
genomic damage as seen as micronucleus frequency is not affected by L-Dopa therapy 
[104].  
5.5 Conclusion  
Overall, we have elucidated the role of ROS induced oxidative DNA damage in three 
models. The NOX organizer protein p47phox plays a crucial role in the formation of the 
oxidatively modified mutagenic marker 8-oxodG in the kidney. Rosuvastatin protected 
the pig kidney cell line LLC-PK1 from Ang II induced 8-oxodG in vitro. An increased 8-
oxodG formation contributed to the oxidative stress burden in PD patients, which was 
compensated by antioxidant effect of L-DOPA.    
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6 Summary  
When there is an imbalance between reactive oxygen species (ROS) and endogenous 
antioxidants (glutathione (GSH), superoxide dismutase (SOD), catalase etc.) the 
oxidative stress is increased and results in the oxidation of lipids, proteins and DNA. 
Although oxidation of lipids and proteins may also accumulates with age, only DNA 
oxidation leads to altered genomic information. As one pathway for increased ROS 
production, many endogenous and exogenous substances activate NADPH oxidase 
(NOX) enzyme and produce ROS. p47phox is a cytosolic organizer protein which plays 
an important role in NOX activation. Angiotensin II (Ang II) is an example for an 
endogenous compound which causes ROS through NOX activation. Rosuvastatin is an 
example for a drug with antioxidative capacity (upregulation of endogenous 
antioxidants). It is a lipid lowering drug which also reduces an elevated level of 
angiotensin II type 1 receptor (AT1R). Commonly, oxidative stress is elevated in ageing 
and age related diseases (eg. Parkinson‟s disease (PD)). The aim of the present study 
was to investigate the role of NOX derived ROS induced oxidative DNA damage and 
the influence of ROS in ageing and age related diseases, using different in vitro and in 
vivo models.  
I)  To quantify oxidative stress and oxidative DNA damage markers, we developed a 
new isotope-diluted-LC-ESI-MS/MS method and validated it to analyze 8-oxodG, 8-
isoPGF2α, GSH, GSSG, Ang II, Aldosterone and creatinine in a single sample 
preparation. The analytes were monitored in the positive and negative multiple 
reaction monitoring (MRM) mode simultaneously. For optimum sensitivity, specific 
product ions and optimal instrument settings were obtained by infusion of authentic 
standards and using the quantitative optimization function of the Analyst 1.4.2 
software. Two transitions per adduct were monitored. Peak areas of the most 
sensitive transitions were used for quantification. Creatinine, GSSG, GSH-NEM, 
dG, 8-nitroG, 8-oxodG and Ang II were analyzed using positive MRM mode. 
Aldosterone and 8-isoPGF2α were analyzed using negative MRM mode. The new 
method shows a LOD of 0.01 pmol on the column for 8-oxodG and 2.5 pmol for 
creatinine. To the best of our knowledge this is the first report for simultaneous 
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analysis of creatinine and 8-oxodG using a stable isotope dilution LC-ESI-MS/MS 
method.  Quantification of 8-isoPGF2α has been suggested as a reliable indicator 
of lipid peroxidation. With our newly developed simultaneous analysis of 8-iso-
PGF2α and creatinine the LOQ was 1.2 fmol and less than 1 fmol for LOD on the 
column. And the method had very good sensitivity and enabled simultaneous 
analysis with creatinine for urinary 8-iso-PGF2α calculation. The method was 
applied to measure urinary and plasma 8-iso-PGF2α. 
GSH is the most abundant intracellular thiol molecule and it plays an essential role 
in maintaining the redox environment. It exists in millimolar (1-10mM) 
concentrations in most cell types. On the other hand, the plasma concentration is in 
the micromolar range, which is approximately 0.4% of total blood GSH. For analysis 
of GSH chemical protection of the thiol group is necessary to prevent GSH 
oxidation completely.  This may be achieved by alkylating SH groups by addition of 
N-ethylmaleimide (NEM) which is a strong and fast alkylation agent. Our sample 
preparation method assures almost 100% protection of GSH from autoxidation by 
the use of excess NEM. Our newly developed LC-ESI-MS/MS method also has the 
advantage of simultaneous analysis of GSH and GSSG, with satisfactory recovery, 
accuracy and linearity. 
Accurate measurement of Ang II and Aldosterone concentrations may be essential 
for correct diagnosis of an elevated renin-angiotensin-aldosterone system. 
Therefore, our new method has the advantage of simultaneous analysis of Ang II 
and aldosterone in urine and plasma.  
This is the first study where simultaneous analysis of 8-oxodG, 8-isoPGF2α, GSH 
and GSSG, dG, 8-nitroG, Ang II, aldosterone and creatinine were performed within 
a single run. The method is applicable to oxidative stress related pre-clinical, 
clinical, and basic research fields. In plasma, GSH, GSSH, 8-isoPGF2α, Ang II, 
aldosterone and creatine are quantifiable, While 8-oxodG, 8-nitroG and dG are not 
detected. In urine, 8-oxodG, GSH, GSSH, 8-isoPGF2α, Ang II, aldosterone, 
creatine and dG are quantifiable. But GSH, GSSG, and dG are not biological 
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relevant and 8-nitroG was not detectable in our study. In tissues, probably all the 
analytes are biological relevant and quantifiable.        
II)  As an in vivo model for investigation of the role of NOX in oxidative DNA damage 
induction, we used the p47phox-/- mouse. The oxidative DNA base modification 8-
oxodG of kidney DNA was significantly different between WT and p47phox-/- mice 
with WT mice showing more 8-oxodG in both young and old age groups. Ang II may 
activate NOX and therefore, a relatively high amount of damage may be caused in 
the kidney where the renin-angiotensin-aldosterone system (RAAS) is locally 
involved with a relatively larg amount of Ang II. Urinary 8-oxodG also showed 
significant differences between WT and p47phox-/- mice in both age groups with WT 
mice showing higher values than phox mice.  
The oxidative stress marker urinary 8-isoPGF2α exhibited a significant difference 
between WT and p47phox-/- in the aged group (WT higher than p47phox-/- mice), 
but not in the young group. Moreover, values were twenty fold higher in aged WT 
mice compared to young WT. The 8-isoPGF2α level in plasma showed a clear 
difference between WT and p47phox-/- mice in the old group. The level was 
significantly higher in old WT than young WT mice. However, we did not see any 
difference in the young group. As another important oxidative stress marker, 
GSSG/GSH ratio was significantly higher in WT mice than p47phox-/- mice in both 
age groups. However, no difference between young and aged mice was seen in 
WT or p47phox-/- mice.    
The amount of urinary Ang II and aldosterone was about four and five fold higher in 
old than in young WT mice. Ang II and Aldosterone showed significant correlation 
between urinary 8-oxodG and 8-isoPGF2α. However, the plasma concentration of 
Ang II and Aldosterone showed no significant difference between the groups. We 
found a significant level of DNA damage in Ang II treated kidney cell isolates of WT 
compared with untreated cells, but no differences in cells from p47phox-/- mice at 
least after short time (30 min) treatment in vitro. Under normal physiological 
conditions, Ang II may regulate redox signaling pathways via NOX activation and 
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ROS production. However, overactivation of RAAS seems to contribute to ageing 
and age related diseases.  
This mouse knockout model demonstrated that the NOX organizer protein p47phox 
plays a crucial role in the formation of the oxidatively modified mutagenic marker 8-
oxodG in the kidney.  
III) The effect of an antioxidant drug was investigated in pig kidney LLC-PK1 cells.  Ang 
II caused oxidative stress, DNA damage and chromosomal aberration in these 
cells.  At 10 nM rosuvastatin prevented DNA strand breaks analyzed by comet 
assay and at 1µM it protected from chromosomal aberrations measured by the 
micronuclei frequency assay. Furthermore, 1µM rosuvastatin was able to protect 
LLC-PK1 cells from elevated oxidative DNA damage. The increased amount of total 
glutathione in Ang II and rosuvastatin treated cells supported the idea that the 
protective effect of rosuvastatin was achieved via the antioxidant effect. 
Rosuvastatin alone upregulated the expression of glutathione synthase, glutathione 
reductase and glutathione peroxidase in LLC-PK1 cells.  The treatment of cells with 
the cholesterol biosynthesis intermediates farnesol, farnesyl pyrophosphate, 
geranylgeraniol did not reverse the action of rosuvastatin. Therefore, rosuvastatin 
action was probably independent of cholesterol biosynthesis inhibition. 
    Rosuvastatin protected the cells from Ang II induced oxidative stress, DNA and 
genomic damage in vitro. The protective effect of rosuvastatin was achieved via 
upregulation of glutathione and it was independent of cholesterol biosynthesis 
inhibition.  
 
IV) As human disease for which ROS is often implied as contributor, Parkinson‟s 
disease was investigated. The oxidative stress biomarker 8-oxodG was elevated in 
chronically L-DOPA-treated patients with PD, which agrees with previous reports 
using post-mortem brain tissue of PD patients. The antioxidative capacity of plasma 
was measured as FRAP. Since low FRAP values indicate high oxidative stress or 
low antioxidant defense level, an inverse correlation with the levels of 8-oxodG might 
be expected. Instead, in our study the antioxidative capacity of plasma was higher in 
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PD patients than in the control group. Elevated DNA oxidation should lead to 
increased genomic damage. However, micronucleus frequencies were not elevated 
compared to the controls. A potential conclusion is that treatment with L-DOPA plus 
dopa decarboxylase inhibitors in our patients might have protected the patients from 
PD-related additional chromosomal damage. 
Overall, the development of a new LC-ESI-MS/MS method enabled a sensitive 
quantification of several oxidative stress related alterations in our models. In 
combination with additional methods, this yielded the new information that the NOX 
organizer protein p47phox plays a crucial role in the formation of the oxidatively 
modified mutagenic marker 8-oxodG. Rosuvastatin protected the pig kidney cell line 
LLC-PK1 from Ang II induced oxidative stress, DNA and genomic damage in vitro in a 
cholesterol biosynthesis independent manner. An increased 8-oxodG formation 
contributed to the oxidative stress burden in PD patients, which was compensated by 
antioxidant effect of L-DOPA.    
Further research will be needed to strengthen the relationship between these findings, 
which will then provide new disease prevention strategies.  
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7 Zusammenfassung  
Bei einem Ungleichgewicht zwischen reaktiven Sauerstoffspezies (ROS) und 
endogenen Antioxidantien (Glutathion (GSH), Superoxiddismutase (SOD), Katalase 
etc.) ist der oxidative Stress erhöht, was zur Oxidation von Lipiden, Proteinen und DNA 
führt. Obwohl auch oxidierte Lipide und Proteine mit steigendem Alter akkumulieren 
können, führen nur DNA-Oxidationen zu veränderter genomischer Information. Ein 
möglicher Signalweg für gesteigerte ROS-Produktion ist die Aktivierung des Enzyms  
NADPH-Oxidase (NOX) und die damit verbundene Generierung von ROS durch viele 
endogene und exogene Substanzen. p47phox ist ein cytosolisches Protein, das eine 
wichtige  Rolle bei der NOX-Aktivierung spielt. Angiotensin II (Ang II) ist ein Beispiel für 
eine endogene Verbindung, die über NOX-Aktivierung ROS produziert. Rosuvastatin ist 
ein Arzneistoff mit antioxidativen Eigenschaften (Hochregulation endogener 
Antioxidantien). Es gehört zur Gruppe der Cholesterinsenker und reduziert ausserdem 
erhöhtes Auftreten des Angiotensin-II-Typ-1-Rezeptors (AT1R). Normalerweise ist 
oxidativer Stress im Alter und bei Alterskrankheiten (z. B.  Parkinson-Krankheit) erhöht. 
Das Ziel der vorliegenden Arbeit war, mit Hilfe unterschiedlicher Modelle in vitro und in 
vivo die Rolle von DNA-Schaden durch NOX-vermittelte ROS zu untersuchen und den 
Einfluss von ROS auf den Alterungsprozess und auf Alterskrankheiten zu bestimmen. 
I) Um oxidativen Stress und oxidativen DNA-Schaden zu quantifizieren, 
entwickelten wir eine neue Isotopenverdünnungs-LC-ESI-MS/MS-Methode 
und validierten diese für eine Analyse von 8-oxodG, 8-isoPGF2α, GSH, 
GSSG, Ang II, Aldosteron und Kreatinin in einer einzigen Probe. Die Analyten 
wurden simultan im positiven und negativen Multiple-Reaction-Monitoring-
Modus (MRM) erfasst. Zur Optimierung der Sensitivität wurden spezifische 
Ionisierungen und optimale Geräteeinstellungen durch Einsatz von 
Standardsubstanzen unter Verwendung quantitativer Optimierungsfunktionen 
der Software Analyst 1.4.2 erreicht.  Je Addukt wurden zwei Übergänge 
detektiert. Die Peakflächen der sensitivsten Übergänge wurden zur 
Quantifizierung genutzt. Kreatinin, GSSG, GSH-NEM, dG, 8-nitroG, 8-oxodG 
und Ang II wurden im positiven MRM-Modus analysiert. Aldosteron und 8-
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isoPGF2α wurden im negativen MRM-Modus analysiert. Mit der neuen 
Methode wurde eine Nachweisgrenze von 0,01 pmol auf der Säule für 8-
oxodG und von 2,5 pmol für Kreatinin erreicht. Nach unserem Wissen ist dies 
der erste Bericht über eine simultane Analyse von Kreatinin und 8-oxodG mit 
einer Isotopenverdünnungs-LC-ESI-MS/MS-Methode. Die Quantifizierung von 
8-isoPGF2α wurde als verlässlicher Indikator für Lipidperoxidation 
vorgeschlagen. Mit unserer neu entwickelten Methode zur simultanen 
Analyse von 8-iso-PGF2α und Kreatinin wurde eine Quantifizierungsgrenze 
von 1,2 fmol und eine Nachweisgrenze von weniger als 1 fmol auf der Säule 
erreicht. Die Methode weist eine hohe Sensitivität auf und ermöglicht die 
simultane Analyse von Kreatinin zur Berechnung des 8-iso-PFG2α im Urin. 
Die Methode wurde eingesetzt um 8-iso-PGF2α im Urin und im Plasma zu 
messen. 
 
GSH ist das häufigste intrazelluläre Thiol-Molekül und spielt eine essentielle 
Rolle bei der Aufrechterhaltung desRedoxstatus. Es kommt in den meisten 
Zellarten in millimolaren (1 - 10 mM) Konzentration vor. Andererseits liegt die 
Plasma-Konzentration im mikromolaren Bereich, was einem Anteil von etwa 
0,4 % des Gesamt-GSH im Blut entspricht. Zur Analyse von GSH ist es 
notwendig, die Thiol-Gruppe chemisch zu schützen um die Oxidation 
vollständig zu verhindern. Dies kann durch Alkylierung der SH-Gruppen mit 
Hilfe von N-Ethylmaleinimid (NEM), einem potenten und schnellen 
Alkylierungs-Agens, erreicht werden. Unsere Probenaufbereitungsmethode 
gewährleistet einen Schutz von GSH vor Autooxidation zu fast 100 % durch 
die Verwendung eines NEM-Überschusses. Unsere neue Methode hat 
darüber hinaus den Vorteil der simultanen Analyse von GSH und GSSG mit 
ausreichender Wiederfindungsrate, Genauigkeit und Linearität. 
 
Die genaue Messung von Ang II und Aldosteron könnte ausschlaggebend für 
eine korrekte Erkennung eines aktivierten Renin-Angiotensin-Systems sein. 
Unsere Methode hat hier den Vorteil der simultanen Analyse von Ang II und 
  Zusammenfassung 
 
105 
 
Aldosteron im Urin und im Plasma. 
 
Die vorgelegte Methode ist die erste Methode zur simultanen Analyse von  8-
oxodG, 8-isoPGF2α, GSH und GSSG, dG, 8-nitroG, Ang II, Aldosteronund 
Kreatinin in einem Lauf. Anwendungsfelder dieser Methode sind präklinische, 
klinische und Grundlagenforschungs-bezogene Fragestellungen im 
Zusammenhang mit oxidativem Stress. Im Plasma waren GSH, GSSH, 8-
isoPGF2α, Ang II, Aldosteronund Kreatin quantifizierbar, während 8-oxodG, 
8-nitroG und dG nicht detektiert wurden.Im Urin wurden 8-oxodG, GSH, 
GSSH, 8-isoPGF2α, Ang II, Aldosteron, Kreatin und dG quantifiziert.GSH, 
GSSG und dG sind jedoch biologisch nicht relevant und 8-nitroG wurde in 
unserer Studie nicht detektiert. Im Gewebe sind vermutlich alle Analyten 
relevant und quantifizierbar. 
 
II) Zur Untersuchung der Rolle der NOX bei der Induktion oxidativen DNA-
Schadens nutzen wir p47phox-/--Mäuse als in-vivo-Modell. Die oxidative DNA-
Basenmodifikation 8-oxodG trat beim WT und bei p47phox-/--Mäusen in 
signifikant unterschiedlichem Maße auf, wobei der WT sowohl in der jungen 
als auch der alten Altersgruppe mehr 8-oxodG aufwies. Ang II könnte NOX 
aktivieren und daher könnte ein relativ hoher DNA-Schaden in der Niere 
auftreten, da hier das Renin-Angiotensin-Aldosteron-System (RAAS) lokal 
eine relativ hohe Menge an Ang II bereitstellt. Die Menge an 8-oxodG im Urin 
war ebenfalls signifikant unterschiedlich zwischen dem WT und p47phox-/--
Mäusen in beiden Altersgruppen, wobei der WT höhere Werte zeigte als die 
phox-Mäuse. 
 
Der Marker für oxidativen Stress 8-isoPGF2α im Urin war signifikant 
unterschiedlich ausgeprägt zwischen WT und p47phox-/--Mäusen in der alten 
Altersgruppe (WT höher als p47phox-/--Mäuse) aber nicht in der jungen 
Altersgruppe. Außerdem waren die Werte bei den alten WT-Mäusen im 
Vergleich zum jungen WTum das Zwanzigfache erhöht. Die 8-isoPGF2α-
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Werte im Plasma zeigten einen klaren Unterschied zwischen WT und 
p47phox-/--Mäusen in der alten Gruppe. Die Werte waren signifikant höher in 
alten WT- als in jungen WT-Mäusen. Wir konnten jedoch keinen Unterschied 
innerhalb der jungen Gruppe beobachten. Ein weiterer wichtiger Marker für 
oxidativen Stress, das Verhältnis GSSG/GSH, war in beiden 
Altersgruppensignifikant höher bei WT-Mäusen als bei p47phox-/--Mäusen. 
Allerdings konnte kein Unterschied zwischen jungen und alten Mäusen 
festgestellt werden, weder im WT noch bei p47phox-/--Mäusen. 
 
Die Menge an Ang II und Aldosteron im Urin war etwa um den Faktor vier 
bzw. fünf erhöht bei alten im Vergleich zu jungen WT-Mäusen. Ang II und 
Aldosteron zeigten signifikante Korrelationen mit 8-oxodG und 8-isoPGF2α im 
Urin. Die Konzentrationen von Ang II und Aldosteron im Plasma zeigten 
jedoch keine signifikanten Unterschiede zwischen den Gruppen. Wir konnten 
eine signifikante Höhe an DNA-Schaden in isolierten Ang-II-behandelten 
Nierenzellen des WT im Vergleich zu unbehandelten Zellen feststellen, 
jedoch zeigten sich keine Unterschiede bei Zellen von p47phox-/--Mäusen 
nach Behandlung für 30 min in vitro. Unter normalen physiologischen 
Umständen könnte Ang II Redox-Signalwege durch eine Aktivierung der NOX 
und einer Produktion von ROS regulieren. Eine Überaktivierung des RAAS 
scheint jedoch am Alterungsprozess und an Alterserkrankungen beteiligt zu 
sein. 
 
Dieses Knockout-Modell zeigte, dass die NOX-Untereinheit p47phox eine 
entscheidende Rolle bei der Bildung des oxidativ modifizierten 8-oxodG, 
einem Marker für Mutagenität, in der Nierespielt.  
 
III) Die Auswirkungen eines antioxidativen Arzneistoffes wurden in den 
Nierenzellen LLC-PK1 untersucht. Ang II verursachte oxidativen Stress, DNA-
Schaden und chromosomale Aberrationen in diesen Zellen. In einer 
Konzentration von 10 nM verhinderte Rosuvastatin die Bildung von DNA-
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Strangbrüchen (Comet Assay) und in einer Konzentration von 1 µM 
verhinderte es das Entstehen chromosomaler Aberrationen (Mikrokerntest). 
Weiterhin schützte Rosuvastatin in einer Konzentration von 1 µM die LLC-
PK1-Zellen vor erhöhtem oxidativen DNA-Schaden. Die erhöhte 
Gesamtmenge an Glutathion in Ang-II- und Rosuvastatin-behandelten Zellen 
unterstützte die Hypothese, dass der schützende Effekt von Rosuvastatin 
durch antioxidative Wirkungen vermittelt wird. Rosuvastatin erhöhtealleindie 
Expression der Glutathionsynthase, der Glutathionreduktase und der 
Glutathionperoxidase in LLC-PK1-Zellen. Behandlung der Zellen mit den 
Cholesterinbiosynthese-Intermediaten Farnesol, Farnesylpyrophosphat und 
Geranylgeraniol machte die Wirkung von Rosuvastatin nicht rückgängig. 
Daher war die Wirkung von Rosuvastatin wahrscheinlich unabhängig von der 
Hemmung der Cholesterinbiosynthese. 
 
Rosuvastatin schützte die Zellen in vitro vor durch Ang II verursachtem 
oxidativen Stress und DNA-Schaden. Der schützende Effekt von 
Rosuvastatin wurde durch eine Hochregulation von Glutathion erreicht und 
war unabhängig von der Hemmung der Cholesterinbiosynthese. 
 
IV) Als Humanerkrankung, die oft mit ROS verbunden wird, wurde die Parkinson-
Erkrankung untersucht. Der Marker für oxidativen Stress 8-oxodG war bei 
Parkinson-Patienten unter chronischer L-DOPA-Behandlung erhöht, dies 
stimmt mit früheren Berichten über post-mortem-Untersuchungen an 
Hirngewebe von Parkinson-Patienten überein. Die antioxidative Kapazität von 
Plasma wurde als FRAP gemessen. Da niedrige FRAP-Werte hohen 
oxidativen Stress bzw. niedrige antioxidative Abwehrmechanismen anzeigen, 
könnte eine inverse Korrelation mit der Höhe an 8-oxodG vermutet werden. 
Im Gegensatz dazu war in unserer Studie die antioxidative Kapazität des 
Plasmas bei Parkinson-Patienten höher als in der Kontrollgruppe. Erhöhte 
DNA-Oxidation sollte zu erhöhtem DNA-Schaden führen. Allerdings waren die 
Mikrokernraten im Vergleich zu Kontrollen nicht erhöht. Eine mögliche 
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Schlussfolgerung ist, dass die Behandlung mit L-DOPA und DOPA-
Decarboxylasehemmern die Patienten vor zusätzlichen, Parkinson-
assoziierten, chromosomalen Schäden geschützt haben könnte. 
Insgesamt ermöglichte die Entwicklung einer neuen LC-ESI-MS/MS-Methode eine 
sensitive Quantifizierung mehrerer, mit oxidativem Stress verbundenen Modifizierungen 
in unseren Modellen. In Kombination mit zusätzlichen Methoden konnte so die neue 
Erkenntnis gewonnen werden, dass die NOX-Untereinheit p47phox eine essentielle 
Rolle bei der Bildung von oxidativ verändertem 8-oxodG, einem Marker für Mutagenität, 
spielt. Rosuvastatinschützte in vitro die Nierenzelllinie LLC-PK1 vor durch Ang II 
verursachtem DNA- und Genomschaden und oxidativem Stress unabhängig von der 
Cholesterinbiosynthese. Gesteigerte 8-oxodG-Bildung erhöhte den oxidativen Stress 
bei Parkinson-Patienten, was durch die antioxidativen Effekte von L-DOPA 
ausgeglichen wurde. 
 
Weitere Untersuchungen sind notwendig, um den Zusammenhang zwischen diesen 
Befunden näher zu charakterisieren. Dies wird zu neuen Präventions-Strategien führen. 
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